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ABSTRACT
Introduction: Multiple comorbidities are common among older adults. Pharmaceutical
interventions are the most common form of medical management of the multiple health
conditions that the older adult population faces. Almost 90% of adults aged 65 years and above
take at least one prescription medication. Polypharmacy (5 medication or more) occurs with 50%
of the older adult population. Most medications used to treat common ailments affecting the
geriatric population have anticholinergic properties. These medications are known to cause a
range of side effects from peripheral effects to central nervous system effects. These adverse
effects are of particular concern in the older population due to age related changes that increases
vulnerability to these side effects. Persistent pain is one of the most common complaint among
older adults. While not the first choice of treatment for pain in this population, the use of opioids
is increasing in the older adult population. Similar to anticholinergics, opioids cause multiple
side effects that may be amplified in older adults. The overarching goal of this dissertation was
to (1) Examine and describe the prescribing trend of anticholinergics and opioids in a population
of community dwelling older adults (2) Assess the effect of anticholinergics on cognitive
function and brain volume of the study population and (3) Assess the effect of opioids on
cognitive function and brain volume of the study population.
Methods: For this dissertation, data from the 60+ cohort of the Personality and Total Health
(PATH) Through Life study (Wave 1 (year 2005/2006) to Wave 4 (year 2014/2015)) were used.
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Medication data of study participants were obtained from the Pharmaceutical Benefits Scheme,
which captures prescription data during the study period for all participants. Medications with
anticholinergic properties were identified using the Anticholinergic Risk Scale, the
Anticholinergic Drug Scale, and the American Geriatrics Society 2012 Beers Criteria.
Medications classified as opioids in the World Health Organization Anatomical Therapeutic
Chemical (ATC) classification was included in this dissertation. To assess the effect of opioids
and anticholinergics on cognition and brain volume, exposure to these medications were
quantified. Exposure to cumulative anticholinergic use was quantified to Total Standardized
Daily Dose (TSDD) and exposure to cumulative opioid use was quantified to Total Morphine
Equivalent Dose (MED). Cognitive measures were obtained from neuropsychological battery
assessment, while magnetic resonance imaging (MRI) was used to obtain volumetric brain
measures. Temporal trends of prescriptions for anticholinergics and opioids from 2004 to 2015
were examined using joinpoint regression analysis. The association between change in cognitive
function and brain volume measures from baseline (wave 2) to 4-year follow-up (wave 3), and
cumulative use of anticholinergics and opioids was assessed through generalized linear models.
Three models were assessed. Model 1 was an unadjusted model, Model 2 adjusted only for
demographic confounders, and Model 3 adjusted for multiple known confounders. Effect
modification of Apolipoprotein E (APOE) epsilon 4 (ε-4) genotype was also assessed. Statistical
significance was determined at p<0.01 to account for potential Type 1 error due to multiple
assessments.
Results: The baseline characteristics of the PATH Through life study were: mean age of 66.6 ±
1.5 years, 51.6% male and mean years of education 13.9 ± 2.6 years. We found that the trend for
anticholinergic prescriptions in the study population increased in 2004 to 2015 with an annual
xiii

percent of change (APC) of 3.4%. While the trend for opioid prescriptions increased from 2004
to 2011 (APC of 11.3%) this trend changed and a decline in prescriptions of opioids was
observed from 2011 to 2015 (APC of -4.4%). Cumulative use of anticholinergics over a period
of 4 years which exceed a TSDD of 1095 was significantly associated with decline in Trail
Making Test Part B (Model 1: β=5.77, Model 2: β=5.33, Model 3: β=8.32, p<0.01). No
significant association was seen between anticholinergic use and brain volume. Among those
exposed to anticholinergics amounting to a TSDD between 366 to 1095, compared to those
without the APOE ε-4 allele, individuals with 2 alleles experienced a significant decline in their
Trail Making Test Part B performance (β=78.82, p<0.01). Compared to those not on opioids,
individuals exposed to opioids resulting in total MED of greater than 2940 had significantly
lower scores in the Mini Mental State Examination (Model 1: β= -0.34, Model 2: β= -0.35, and
Model 3: β= -0.39, p<0.01). Among those with this highest level of cumulative opioid exposure,
individuals with two APOE ε-4 alleles had significantly greater decline in their Immediate Recall
( β= -5.71, p<0.01) and Delayed Recall (β= -7.38, p<0.001) assessments compared to those
without the alleles. Opioid use was not significantly associated with changes in brain volume and
white matter hypointensities during the study period.
Conclusion: Results from this dissertation show that among older adults, chronic exposure to
high doses of anticholinergics and opioids result in greater cognitive decline. While
pharmaceutical management of comorbidities in this population is inevitable, these findings
support the need to approach the use of these medications with caution in geriatric populations to
avoid adversely affecting healthy aging trajectories and cognitive health of older adults.
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CHAPTER 1
INTRODUCTION
The use of pharmaceuticals for medical management of chronic conditions is inevitable
in older adults. Among individuals aged 65 years and above, almost 90% are prescribed at least
one medication, of which 50% are on five or more medications at a time.(1, 2)
Medications with anticholinergic properties are of concern in older adults, as most
medications used to treat comorbidities that come with aging have some anticholinergic
properties. Anticholinergics are an integral part of the treatment regimen of conditions such as
urinary incontinence, asthma, and numerous psychiatric conditions.(3) While guidelines for use
of anticholinergics in older adults caution that the risks may exceed the benefits in this
vulnerable population,(3-5) the prevalence of use of these medications still ranges between 8% to
37%.(6-9)
Similarly, prescription of opioids in older adults is also on the rise.(10) Persistent pain is
a common complaint among older adults. Almost 80% of older adults living in nursing homes
report suffering from persistent pain. In community dwelling older adults, this complaint is
reported among 50% of the population.(11) Although opioids are not recommended as the first
line of treatment for pain in older adults, they are being prescribed more commonly and for
longer durations.(12-14) Opioids cause sedation which can lead to multiple adverse effects in
older adults, from increased risk of falls to reduction in cognitive performance.(15)
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While medications with anticholinergic properties and opioids are known to cause side
effects in both the central and peripheral nervous systems in older adults, (16-20) their effects on
cognitive impairment is of concern. While decline in cognitive performance in older adults is
often attributed to age-related changes to the brain,(21) the risk factors for cognitive impairment
are multifactorial.(22) With the increasing prevalence of dementia globally and its devastating
effect on the economic burden of the condition and implications on care-givers, understanding
risk factors, such as prescription medication use can provide important insights into the
development of effective prevention strategies.
BACKGROUND & SIGNIFICANCE
Between the year 1988 and 2010, polypharmacy (five or more medications) among older
adults increased from 13% to 39% (23) and was associated with adverse drug reaction.(24-26)
Additionally, polypharmacy is also reported to increase the risk of prescribing potentially
inappropriate medications in older adults.(27)
Multiple chronic conditions, which are common in older adults, are treated with
medications with anticholinergic properties.(3) Among older adults over the age of 65 years in
the United States, 62% have multiple chronic conditions. By the year 2020, 81 million of
Americans are projected to live with multiple chronic conditions.(14)
Approximately 40% of institutionalized older adults and 50% of older adults in the
community take at least one anticholinergic drug.(28, 29) Older adults are particularly sensitive
to the side effects of medications with anticholinergic properties. This is because age increases
permeability of the blood-brain barrier, reduces the cholinergic receptors in the brain and
changes the efficiency of hepatic and renal function.(30) While initial studies reported the
2

adverse effects of anticholinergics to be transient and reversible upon medication
discontinuation, newer studies have indicated that anticholinergics may play a role in the
pathophysiology of cognitive impairment.(7, 29, 31)
The prevalence of opioid use has increased significantly in older adults.(10) This is
mainly due to the increase in chronic pain as we age, greater awareness of pain management and
newer opioids marketed as having fewer adverse effects. (32-35) There is evidence for the
association between opioid use and delirium in older adults.(36) Opioids modulate microglia
behavior (37) and inflammation mediating immune response in the brain,(38) suggesting a
possible association to neurodegenerative diseases. This is further supported by findings from
autopsy examinations of young substance abusers that indicate neuropathological changes
similar to Alzheimer’s Disease (AD).(37, 39)
While studies have attempted to assess the association between anticholinergic
medications, opioids and cognition, they have methodological limitations that this study will aim
to address. The objective of this study is to assess this association while employing several
methodological methods to address limitations in past studies. The large population-based
sample, verification of medication use through a national database and comprehensive
neuropsychology assessments are strengths of this dissertation. By assessing changes in
structural brain volumes via MRI and the role of apolipoprotein-e4 allele as an effect modifier,
this dissertation aims to address pertinent gaps in the literature.

3

CHAPTER 2
SPECIFIC AIMS
The purpose of this dissertation is to determine whether the use of opioids and
medications with anticholinergic properties among the older adults are associated with an
increased risk for dementia. This will be determined by pursuing the following specific aims:
Aim 1: Describe the prescribing trend of medications with anticholinergic properties and
opioids among individuals aged 60 and above.
Objective 1: Determine if there is a significant change in the prescribing trend of medications
with anticholinergic properties and opioids over a period of 10 years among participants in the
60+ cohort of the PATH through Life study.
Aim 2: Examine the association between the use of medications with anticholinergic
properties among individuals aged 60 and above, and subsequent cognitive impairment.
Objective 2.1: Determine the association between the change in neuropsychology tests scores
over a period of 4 years among participants in the 60+ cohort of the PATH through Life study
and the use of medications with anticholinergic properties.
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Hypothesis 2.1: We hypothesize that compared to those not on medications with anticholinergic
properties, individuals on medications with anticholinergic properties will have a significantly
higher decline in their neuropsychology tests scores.
Objective 2.2: Determine if the presence of apolipoprotein ε-4 allele (APOE-ε4) modifies the
association between the change in neuropsychology tests scores over a period of 4 years among
participants in the 60+ cohort of the PATH through Life study and the use of medications with
anticholinergic properties.
Hypothesis 2.2: We hypothesize that individuals with the APOE-ε4 gene and on medications
with anticholinergic properties will have a significantly higher decline in their neuropsychology
tests scores.
Aim 3: Examine the association between the use of medications with anticholinergic
properties among individuals aged 60 and above, and subsequent change in brain volume.
Objective 3.1: Determine the association between change in brain volume over a period of 4
years among participants in the 60+ cohort of the PATH through Life study and the use of
medications with anticholinergic properties.
Hypothesis 3.1: We hypothesize that compared to those not on medications with anticholinergic
properties, individuals on medications with anticholinergic properties will have a significantly
higher decline in brain volume.
Objective 3.2: Determine if the presence of apolipoprotein ε-4 allele (APOE-ε4) modifies the
association between the change in neuropsychology tests scores over a period of 4 years among
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participants in the 60+ cohort of the PATH through Life study and the use of medications with
anticholinergic properties.
Hypothesis 3.2: We hypothesize that individuals with the APOE-ε4 gene and on medications
with anticholinergic properties will have a significantly higher decline in brain volume.
Aim 4: Examine the association between the use of opioids among individuals aged 60 and
above, and subsequent cognitive impairment.
Objective 4.1: Determine the association between the change in neuropsychology tests scores
over a period of 4 years among participants in the 60+ cohort of the PATH through Life study
and the use of opioids.
Hypothesis 4.1: We hypothesize that compared to those not on opioids, individuals on opioids
will have a significantly higher decline in their neuropsychology tests scores.
Objective 4.2: Determine if the presence of apolipoprotein ε-4 allele (APOE-ε4) modifies the
association between the change in neuropsychology tests scores over a period of 4 years among
participants in the 60+ cohort of the PATH through Life study and the use of opioids.
Hypothesis 4.2: We hypothesize that individuals with the APOE-ε4 gene and on opioids will
have a significantly higher decline in their neuropsychology tests scores.
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Aim 5: Examine the association between the use of opioids among individuals aged 60 and
above, and subsequent change in brain volume.
Objective 5.1: Determine the association between change in brain volume over a period of 4
years among participants in the 60+ cohort of the PATH through Life study and the use of
opioids.
Hypothesis 5.1: We hypothesize that compared to those not on opioids, individuals on opioids
will have a significantly higher rate of decline in brain volume.
Objective 5.2: Determine if the presence of apolipoprotein ε-4 allele (APOE-ε4) modifies the
association between the change in brain volume over a period of 4 years among participants in
the 60+ cohort of the PATH through Life study and the use opioids.
Hypothesis 5.2: We hypothesize that individuals with the APOE-ε4 gene and on opioids will
have a significantly higher decline in brain volume.
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CHAPTER 3
COGNITIVE IMPAIRMENT AND DEMENTIA
This section briefly introduces the concept of mild cognitive impairment and dementia as
well as their respective epidemiology. It also further presents the risk factors generally associated
with dementia. This section will also discuss the assessment of cognitive decline in terms of a
neuropsychology battery and magnetic resonance imaging (MRI).
MILD COGNITIVE IMPAIRMENT & DEMENTIA
Mild Cognitive Impairment
Mild cognitive impairment (MCI) is the prodromal state that precedes dementia. MCI is
defined as a decline in cognition that is greater than expected, based on an individual’s age and
education level, that does not significantly affect one’s independent daily functioning.(40) While
the initial definition of MCI required memory impairment for diagnosis,(41) MCI was later
defined as a spectrum of conditions in the intermediate stage between normal cognition and
dementia, comprised of impairment in both memory and non-memory domains.(42-44) The
diagnostic criteria for MCI is described in Table 1.
MCI is heterogenous in its clinical presentation. Amnestic MCI (aMCI), which is most
common, presents with impaired memory. Absence of impaired memory with impairment in one
or more of other cognitive domains is classified as non-amnestic MCI (naMCI). Table 2 further
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details the differences between aMCI and naMCI. MCI may also present as impairment in a
single cognitive domain or in multiple domains, implying the extent of pathology in the
brain.(45)
Table 1: The National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria for
diagnosing MCI (45, 46)
•

Changes is an individual’s cognitive function as reported by the individual or an
informant with knowledge of individual’s cognitive status, or as observed by a
clinician assessing the patient.

•

Evidence from neuropsychological assessment indicating an individual’s impairment
in one or more cognitive domains.

•

The individual’s independent functional abilities are preserved although they can be
less efficient.

•

The individual does not show significant impairment in their social or occupational
functioning.

Table 2: Subtypes of mild cognitive impairment by etiology, pathology, presentation and
outcomes (45)
Variable

Amnestic-MCI

Non-amnestic MCI

Etiology

Neurodegenerative disease

Vascular damage

Apolipoprotein- e4 allele

Cerebrovascular disease

Neurodegenerative

Cerebrovascular

Amyloid β plaques

Cortical infarctions

Neurofibrillary tangles

Subcortical infarctions

Hippocampal atrophy

White matter hyperintensities

Pathology

Reduced brain volume
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Presentation

Memory impairment present

Impairment in non-memory
domains

Alzheimer’s disease (AD)

Long term
outcomes

Non-Alzheimer’s dementias:
vascular, Lewy body,
frontotemporal

Reprinted from Clinics in Geriatric Medicine 29/4, Roberts & Knopman, “Classification and
Epidemiology of MCI”, 753-772, Copyright 2013, with permission from Elsevier

Prevalence and Incidence of Mild Cognitive Impairment
Studies conducted in clinical as well as population samples have reported the prevalence
of MCI in individuals ages 65 years and above to range between 10% to 20%.(47, 48) Prevalence
of MCI increases with age.(48) In those aged 70 years and above, the prevalence of MCI is
reported to range between 15% to 25%.(43)
Studies on the incidence of MCI report a wide range of incidence rates, ranging from as
low as 5.1 to as high as 168 (per 1000 person years).(45, 49-57) Estimates of prevalence and
incidence rates of mild cognitive impairment vary due to methodological factors such as the
sample population and diagnostic criterion used in the study. Incidence of aMCI is reported to be
higher compared to naMCI, with one study reporting the rates as 37.7 and 14.7 (per 1000-person
years) respectively.(58)
Dementia
Dementia is characterized as a progressive decline in cognitive function that affects social
and/or occupational functioning of an individual.(59) There are multiple subtypes of dementia,
which vary in their clinical presentation and neuropathology. The main subtypes of dementia are
further described in Table 3.
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Table 3: Main subtypes of dementia (59)
Subtype

Primary
impairments/disability/symptoms

Pathology/causes

Alzheimer’s disease

Memory, language and functional
disability

Neuritic plaques (proteinaceous
extra-cellular deposits consisting
mainly of amyloid-beta peptide
fragments) and neurofibrillary
tangles (twisted fibers of a protein
called tau)

Vascular dementia

Poor concentration and communication
and physical symptoms such as
paralysis or weakness in limbs

Problems of circulation of blood
to the brain – related to stroke,
high blood pressure
(hypertension), diabetes and heart
problems

Dementia with Lewy
bodies

Hallucinations, spatial disorientation,
impaired recent memory and
fluctuations in mental performance

Presence of Lewy bodies which
refer to abnormal structures
within nerve cells of the brain

Frontal lobe dementia

Changes in personality and behavior,
and emotional and language
dysfunction. No dysfunction in memory

Frontal lobe degeneration

Pick’s disease

Impairment in emotional and social
functioning

Abnormalities in Pick’s bodies.
Focal damage in the frontal and
temporal lobes

Alcohol related
dementia – Korsakoff’s
syndrome

Impaired memory, planning,
organizing, judgement, social skills and
balance

Chronic/excessive alcohol intake

Prevalence and Incidence of Dementia
The prevalence of dementia among individuals aged 60 years and above is reported to
range between 5 to 7%. Based on this rate, there are approximately 34.4 million individuals
living with dementia globally.(60) Every 20 years, the global prevalence of dementia is expected
to double, potentially leading to approximately 81 million dementia cases by the year 2040. Of
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these cases, it is estimated that 71% will be living in developing countries.(61) The prevalence of
dementia is also reported for increase with age, almost doubling every five years in those aged
65 years and above.(62)
A systematic review of dementia incidence studies reported the pooled incidence of
dementia to be 52.8 per 1000, with the incidence rate in the individual studies ranging from 8.7
to 142.2 per 1000.(63) The incidence of dementia increases with age, with an exponential
increase in those aged 65 years and older.(64, 65) In the 65 to 69 age group, the incidence of
dementia is reported to be 2.4 per 1000 person years. This rate increases to 70.2 per 1000-person
years in those aged 90 years and above. While the incidence rate increases with age in women, it
appears to plateau at the age of 85 for men.(66)
RISK FACTORS OF DEMENTIA
Dementia is a multi-factorial disease, with multiple risk factors that may lead to the
disease. This section will further elaborate risk factors of dementia that are of interest in this
dissertation based on the conceptual framework of the dissertation shown in Figure 1.
Demographic Risk Factors:
The demographic risk factors of interest in this dissertation are age, sex, and education
level.
Age
Age is an important covariate in studies investigating the different dementias. Taking the
example of Alzheimer’s disease (AD), the doubling of prevalence rate every 5 years was first
reported by Jorm and colleagues, who reported prevalence rates of AD to be 0.7% (60 to 64
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years), 1.4% (65 to 69 years), 2.8% (70 to 74 years), 5.6% (75 to 79 years), 10.5% (80 to 84
years), 20.8% (85 to 89 years) and 38.6% (90 to 95 years). (67) This finding is corroborated by
subsequent studies.(68) Studies have also shown that prevalence of AD continues to increase as
we age, even in those above 85 years old (oldest-old).(69) However, autopsy studies in the very
old report a decline in the association between AD pathology and clinical dementia, (70, 71)
suggesting the role of other pathologies that push an individual over the cognitive threshold to
express clinical AD.
Incidence rates of AD in different age groups vary across studies mainly due to the
variation in the methodology of case definition.(72) However, regardless of the methodological
variations, the pattern of increasing incidence as age increases remains.(62)
Sex
In the case of AD, prevalence rates in men and women has varied across studies, with
some studies finding higher prevalence rates in women (73-75) and others finding similar rates in
both men and women after age adjustment.(76) Prevalence of AD has also been reported to be
lower in women between the ages 60 to 70 years, while higher in women ages 85 years and
above (oldest-old).(76)
Meta-analysis on incidence rates have shown that while women were not at a higher risk
for dementia compared to men (OR=1.18, 95% CI =0.95-1.46) they may be at a higher risk for
AD (OR=1.56, 95% CI=1.16-2.10).(77) Other studies have also corroborated the finding of
higher risk of AD among women.(62, 78) However, there have also been evidence showing that
sex does not have a significant effect on the risk of AD.(79-81)
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Prevalence and incidence rates of AD among men and women are influenced by life
expectancies by sex, differences in education among men and women, and the possible lack of
the protective effect of estrogen upon menopause in women.(72)
Education level
Low education levels appear to be a risk factor for dementia. In a sample of elderly
individuals in New Haven, Connecticut, severe cognitive impairment was found to be highly
correlated with education levels.(82) The study found the rate of severe cognitive impairment to
be 0.2% in those with 16 years of education or more and 6.1% in those with 8 years of education
or lesser. One study showed that prevalence of dementia was significantly higher in those with
no education compared to those with formal education.(83)
These findings have been corroborated by several other systematic reviews and metaanalyses. These meta-analyses show that low education increases the risk of dementia: RR=1.59
(95%CI =1.43-2.27)(84), RR=1.89 (95% CI =1.61-2.22)(85) and RR=1.88 (95% CI =1.512.34).(86) Pooled estimates of risk of Alzheimer’s disease in those with low education was
higher compared to that of dementia: 1.80 (versus 1.59 in dementia).(84)
Several hypotheses have been discussed to describe why low education appears to be a
strong risk factor for dementia such as lower education leading to more rapid accumulation of
AD pathology, low education being related to other risk factors of AD and education possibly
being a surrogate for cognitive abilities. (87)
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Figure 1: Conceptual Framework
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Lifestyle Risk Factors:
The lifestyle risk factors of interest in this dissertation are smoking, alcohol consumption
and physical activity.
Alcohol consumption
There have been several meta-analyses looking at the association between alcohol
consumption and cognitive decline. One pooled analysis of case-control studies in AD showed
no effect of alcohol.(88) A meta-analysis on prospective cohort studies, with 13-point estimates
specifically on AD showed a pooled RR of 0.57 (95% CI:0.44-.74).(89) However the authors
highlight the methodological issues in comparing these studies due to the non-uniformed way
exposures were defined and varying follow-up periods. Another pooled meta-analysis by
Cummings and colleagues reported that for light to moderate drinkers compared to teetotalers,
the pooled RR for AD is 0.72 (95% CI= 0.61-0.86), with a stronger association in men compared
to women.(90) The authors however did not find a significant association in heavy drinkers
compared to teetotalers. In the Italian Longitudinal Study on Aging, the authors found that for
MCI to dementia transitions, there was a significant inverse association in those having one or
less drinks per day compared to no drinks per day (HR=0.15, 95% CI =0.03-0.78).(91)
Studies looking specifically at wine consumption and risk of AD also appear to show a
protective effect of moderate wine consumption.(92-94) One study showed that compared to
non-drinkers, mild drinkers (of mainly wine) had a reduced risk for AD (OR=0.55, 95%
CI=0.31-0.99).(93) Another study in Denmark found that compared to individuals who never or
hardly consumed wine, those who consumed wine on a monthly basis had a reduced risk for AD
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(OR 0.43, 95% CI=0.23-0.82). Similarly, risk of AD was also reduced in those who consumed
wine weekly (OR=0.33, 95% CI=0.13-0.86).(94)
Many mechanisms have been suggested to support the protective effect of low to
moderate alcohol intake.(95-97) Studies have shown lesser white matter damage (97) and
reduced white matter hyperintensities (98) in low-moderate drinkers compared to teetotalers.
Physical activity
Studies have shown that greater physical activity is associated with lesser cognitive
decline and thus a lower risk for dementia.(99, 100) One meta-analysis of cohort studies
assessing the association of physical activity and incident AD showed that greater physical
activity was associated with lower risk of AD (pooled RR=0.58, 95% CI= 0.49-0.70) and the
proportion of dementia cases attributable to low physical activity was 31.9% (95% CI=22.7%41.2%).(101) However, there are some studies that did not find an association between physical
activity and risk of dementia,(102, 103) suggesting that the association found in the other studies
could be due to reverse causation, where the reduction in physical activity was due to prodromal
onset of AD.
Addressing the possible reverse causality, studies examining physical activity in mid-life
showed the protective effect of physical activity in mid-life on dementia.(104, 105) One casecontrol study assessing the effect of exercise in midlife and AD among twins, found that those
who regularly exercised in mid-life, had a lower risk of developing AD in late life (OR= 0.34,
95% CI=0.14-0.86).(105) Studies have also consistently shown that individuals who exercise
more have larger cortical gray matter volumes,(106, 107) larger hippocampal volume(108) and
larger brain volumes.(108)
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Smoking
Increased risk of dementia is significantly associated with smoking. Currently smokers
have an increased risk of dementia and quitting smoking can reduce this risk.(109) Current
smokers have a 40% increased risk of developing AD and 38% increased risk of developing
vascular dementia.(109) Chronic smoking, which exposes the smoker to nicotine, also exposes
the body to a continued state of oxidative stress, which promotes AD neuropathology.(110)
Smoking is also associated with an increase in other cardiovascular risk factors, such as stroke,
hypertension and diabetes, which can increase the risk of dementia.(111-114)
Clinical Risk Factors:
The clinical risk factors of interest in this dissertation are stroke, diabetes, hypertension,
body mass index, depression and family history of dementia.
Family History of Dementia
Family history is one of the strongest risk factors for dementia.(72) In a study on AD,
Sjorgen and colleagues published the first systematic study investigating familial aggregation of
presenile cases, showing increased risk of a similar disease in parents and siblings.(115) Another
important study, by Heston and colleagues showed that the earlier the onset of disease, the
stronger the risk to siblings, indicating a strong association between risk to siblings and age at
which a person became symptomatic.(116) Pooled re-analysis of case control studies on AD
further supported this evidence showing the increased risk of disease to blood relatives of
patients who developed onset of disease before the age of 70, with a pooled OR of 3.5 (95%
CI=2.6-4.6) for those with history of dementia in first degree blood relatives.(117) Twin studies
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were further able to effectively study the role of genetics in AD. The largest twin study of
dementia, by Gatz and colleagues showed that the heritability for AD is 79% (95% CI= 67%88%). (118)
Three genetic mutations that cause AD were identified, further strengthening the role of
family history in AD. These were the mutation in the gene for Amyloid Precursor Protein (APP)
on chromosome 21(119), presenilin 1 gene (PSEN1) in chromosome 14(120) and the presenilin 2
gene (PSEN2).(121) Onset age for individuals with the APP gene mutations is between the 40s
and 50s,(122) while those with the PSEN1 account for almost half of all early-onset AD, with
onset age from 29 years to 62 years.(120) PSEN 2 is also linked to early onset of AD, with onset
age ranging from 40 years to 80 years.(121)
Stroke
The vascular system in the brain plays an important role in protecting the neurovascular
structure through sufficient blood flow to the brain and the integrity of the blood brain
barrier.(123) Cerebrovascular events such as strokes and transient ischemic attacks (TIA) have
been suggested to eventually lead to neurodegenerative processes by reducing the cerebral blood
flow, which over time affects the neurons, synapses and neurotransmission in the brain(124),
leading to the speculation that vascular lesion in the brain may also cause AD pathology.
However, autopsy studies show that vascular lesions and AD lesions appear to occur
independently.(72)
Yet studies such as the Religious Order Study reported that cerebral infarcts were
associated with dementia risk,(125) indicating that AD pathology and cerebral infarcts act
additively to the risk for dementia.(126) The investigators of the MAP study, who also found
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that the joint effects of AD pathology and cerebral infarcts have no interaction beyond an
additive effect, suggested that the cerebrovascular lesions cause the brain to have a lower ability
to actually tolerate a given amount of AD pathology, thus causing an individual to show signs of
cognitive impairment. The authors further suggested that the prevention of cerebrovascular
disease may reduce the number of individuals with the clinical criteria of AD.(125) Subclinical
vascular lesions, such as lacunar infarcts and white matter hyperintensities (WMH) have also
been found to be associated with cognition in the elderly.(127)
Diabetes
Presence of diabetes increases the risk of dementia. Both cross-sectional and prospective
studies have shown that diabetes increases the risk of cognitive impairment, particularly in
executive function and memory domains.(128-132) The effect of diabetes on dementia can be
explained by several pathways of action. Diabetes can cause vascular changes, at the macro and
micro level that can explain the increased risk of vascular dementia.(132, 133) It is also
suggested that diabetes can lead to dementia through its effect on insulin regulation. Insulin plays
an important role in memory consolidation.(97) In diabetes, insulin levels are altered, which
could increase inflammation activity and oxidative stress. This can promote the accumulation of
AD neuropathology.(134-136)
Hypertension
Hypertension is one of the most important risk factors for vascular dementia.(137)
Hypertension is reported to be associated with poor performance in episodic memory as well as
global cognition.(138) The role of hypertension in the risk elevation of vascular dementia can be
explained by its impact of overall vascular health. Chronic hypertension decreases the elasticity
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of blood vessels and reduces their ability to respond to tissue demands.(139-141) This affects
cerebral blood flow, encouraging cerebrovascular injury and lesion in the brain that result in an
increased risk for vascular dementia.(138, 142, 143)
Body Mass Index (BMI)
Obesity has been shown to increase the risk of dementia. Studies show that obesity in
midlife increased the risk of dementia by 41%.(144) Obesity not only impairs normal cognitive
performance, it also further affects cognitive function that is on a decline. (145, 146) The effect
of obesity on cognitive decline may be direct, as obesity increases adipose tissue in the body.
High adipose tissue in the body further increases secretion of hormones and cytokines which
may adversely affect brain health.(147) Obesity also increases the risk of conditions that affect
cardiovascular health such as hypertension, diabetes and hyperlipidemia. The mediation of these
pathways may be an indirect way of how obesity affects cognitive health.(147)
Depression
Several studies have linked depression to an increased risk of developing dementia. One
study found that individuals with prolonged clinical depression at a young age are at an increased
risk of developing dementia.(148) High depressive symptoms and increasing depressive
symptoms appear to be an independent risk factor for incident dementia. In their study,
Saczynski and colleagues found a 76% increase in the risk of developing AD among individuals
who reported depressive symptoms.(149) Severe depression in later life increases the risk of AD
by 104%.(150)

21

Several potential pathways have been suggested to explain the association between
depression and dementia. It is suggested that chronic inflammation, possibly due to emotional
and mental stress, is present in depression and this can lead to dementia.(151) Depression can
also lead to dementia pathology by increasing inflammatory agents such as interleukin-6, tumor
necrosis factor-α and C-reactive protein.(151, 152) A meta-analysis by Koolschijn and
colleagues found that depression was associated with reduction in hippocampal volume, that may
explain the role of depression in dementia.(153)
Effect Modification of Apolipoprotein E (APOE) epsilon 4 (ε-4) genotype
APOE ε-4 is an effect modifier of interest in this dissertation. The high heritability of
dementia suggests that the roles played by genes extends further than just mutations. This leads
to the importance of investigating the effect modification of genetics on the association between
exposures of interest and dementia. The gene for APOE was discovered on chromosome 19 as a
susceptibility gene for AD.(154, 155) A meta-analysis of case-control studies on APOE showed
an increased risk for individuals with AD over 65 years old to have one or more APOE-ε4
alleles with a pooled OR of 3.18 (95% CI= 2.93-3.45).(156)
ASSESSING COGNITION USING NEUROPSYCHOLOGY TESTS
Introduction to neuropsychological assessments
Cognitive impairment presents as complaints and symptoms, which needs to be evaluated
in terms of functional capacity through neuropsychological tests. Cognitive functioning includes
a myriad of abilities encompassing multiple cognitive domains, namely memory, visual-spatial
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abilities, language, processing speed, attention and concentration, psychomotor functioning, and
intellectual capacity. (157, 158)
Evaluation of cognitive function cannot rely completely on self-reported complaints and
clinical interviews alone. Past studies have reported that individuals with cognitive impairment
are poor reporters of their individual cognitive functioning.(159-162) Additionally, clinical
interviews without neuropsychological tests has been found to be poor evaluation of cognitive
function, further proving the importance of neuropsychological assessment in the evaluation of
cognition.(161)
Essentially, neuropsychological assessments aim to investigate the behavioral outcomes
due to changes in the brain, through standardized scaled tests and guided interviews. It is
commonly used to evaluate cognitive outcomes due to conditions such as brain damage,
neurological conditions and psychiatric illnesses. Performed through a battery approach,
neuropsychological assessment data are collected by a trained examiner.(163)
Neuropsychological assessments have multiple uses. They are useful in differentiating
neurological symptoms from psychiatric ones, identifying the different neurological conditions
that resulted in the symptoms and providing evidence to inform the site of the brain lesion
causing the symptoms.(158) While advances in neuroimaging technologies have enabled us to
identify affected areas of the brain, similar findings on neuroimaging tests (similar location of
lesions) need not necessarily present with similar functional impairments in all individuals. (70,
164) This elucidates the necessity of neuropsychological assessments as an essential part of
diagnostic protocols for cognitive function.
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Additionally, neuropsychological assessments play an important role in differential
diagnosis. An example of this is the deferential diagnosis of dementia from amnesia. The former
requires memory impairment to be present with impairments in other cognitive domains, while
amnesia is diagnosed with memory deficits alone. Neuropsychological assessment, which allows
detection of impairments in multiple cognitive domains facilitates deferential diagnosis such as
this. (163)
Successive neuropsychological assessments can provide insightful information on the
direction and rate of change of the cognitive repercussion due to the underlying neurological
condition.(165) Neuropsychological assessments can also demonstrate the effects of an
intervention or medication on cognition.(166, 167)
Cognitive domains and appropriate neuropsychology tests
When examining neurocognitive disorders, it is vital to clearly delineate and assess the
individual domains of cognitive function. Figure 2 depicts the classification of six principal
cognitive function domains by the Neurocognitive Work Group for the DSM-5. The six principal
domains are social cognition, learning and memory, perceptual-motor function, language,
executive function, and complex attention.(168)
Complex Attention
The concept of complex attention consists of sustained attention, selective attention,
divided attention and processing speed.(169) The concept of attention refers to an individual’s
capability to sustain their attention when faced with ordinary distractions. Individuals with
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unimpaired complex attention are able to sustain, divide, shift as well as share their
attention.(170)

Figure 2: Neurocognitive domains as defined in DSM-5 (168)
Reprinted by permission from Springer Nature: Nature Reviews Neurology, 10/11, :”Classifying
neurocognitive disorders: the DSM-5 approach”, Sachdev et al, Copyright 2014

Complex attention impairment can be either severe or mild. Severe impairment in the
complex attention domain often presents as difficulty in environments with multiple stimuli,
leading to distraction and inability to pay attention when faced with simultaneous competing
events. These individuals are also often unable to recall immediate information, and perform
mental calculations.(169) Mild impairment in this cognitive domain presents with symptoms
such as taking a longer time than usual to complete normal tasks, making errors in routine tasks
and finding it easier to think in environments free of distractions.(169) Complex attention is

25

assessed through the evaluation of sustained attention, selective attention and divided attention,
by measuring the processing speed in completing relevant tasks. (169)
Executive Function
Executive function includes concepts such as working memory, decision making,
planning, feedback/error utilization, overriding habits/inhibition and mental flexibility.(169, 171)
Severe impairment in the executive function domain presents with symptoms such as abandoning
complex tasks/projects, needing to focus on one task at a time and dependence on others to make
decisions and to plan instrumental activities of daily living. Mild impairment in the executive
function domain can presents as the need to have increased effort to complete complex projects,
having increased difficulty resuming a task once interrupted, having difficulty in completing
multiple tasks simultaneously. It can also present as fatigue from the effort to needed to plan and
make decisions or finding social interactions in larger groups to be taxing because of the effort
needed to participate in shifting conversations.(169)
Neuropsychological assessments that evaluate impairment in the executive function
domain will focus on assessing the concepts of this domain. These include tests such as those
requiring interpretation of sequential arrangement of pictures or object, recalling and
manipulating information and decision making ability when presented with competing
alternatives, to name a few. (169)
Learning and Memory
Learning and memory refers to the ability to understand and store new information.
Learning and memory includes concepts such as immediate memory, recent memory and longterm memory.(169, 170) Severe impairment in the learning and memory domain presents with
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symptoms such as inability to orient to tasks without frequent reminders, inability to recall short
lists of items and repeating one’s phrases during a conversation. Mild impairment in the learning
and memory domain can present as difficulty in recalling recent events and needing
reminders.(169) Neuropsychological assessment to evaluate learning and memory will focus on
assessing immediate memory span as well as recent memory. These are done through tasks that
require an individual to repeat words or digits and tasks that require encoding new
information.(169)
Language
The domain of language comprises of expressive language and receptive language. It
reflects the ability of an individual to understand and communicate using language, and to
comply with instructions given in the language. Individuals with severe impairment in this
domain usually present with symptoms such as difficulty with receptive or expressive language.
Individuals with mild impairment in the language domain present with symptoms such as having
difficulty in finding words, making grammatical errors due to omission or incorrect word usage,
and purposely choosing to avoid the use of specific names. Impairment in the language domain
of cognition is assessed through tasks that require comprehension, fluency, and grammar and
syntax skills.(169)
Perceptual – motor
The perceptual – motor domain includes visual perception, visual construction,
perceptual – motor, praxis and gnosis. Individuals with severe impairment in this domain will
present with symptoms such as having profound difficulty in activities which were previously
familiar to them and facing challenges in navigating familiar environments. On the other hand,
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individuals with mild impairment in this domain may present with symptoms such as needing to
rely on directions and maps more than usual, losing oneself when not concentrating on the task at
hand, and requiring greater effort than usual for spatial tasks.(169) Impairment in this domain
can be assessed with tasks requiring hand-eye coordination, tasks needing the integration of
perception with purposeful movement, and tasks which assess the ability to accurately perform
learned movements, to name a few. (169)
Social cognition
The domain of social cognition includes the concept of emotion recognition and
theory of mind. Individuals with severe impairment in this domain show symptoms such as
socially unacceptable behavior, insensitivity to social standards, disregard to family and friends,
and disregard to safety when making decisions is seen. Symptoms such as subtle changes in
attitude, subtle changes in personality and decrease in social cue recognition are seen among
individuals with mild impairment in the social cognition domain.(169) Neuropsychological
assessment of impairment in this domain include tasks such as those requiring the individual to
identify the emotion behind visual presentations and tasks requiring the ability to perceive and
consider another individual experience or state of mind.(169)
ASSESSING COGNITION USING NEUROIMAGING MEASURES
Introduction to neuroimaging in dementia
Through advances in neuroimaging techniques and technology, evaluation of dementia
now routinely includes a brain imaging component. These advances have led to the identification
of neuroimaging biomarkers for dementia, information on disease prognosis, and understanding
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of the underlying pathology resulting in the clinical dementia symptoms.(172) The use of
structural brain imaging is recommended by the American Academy of Neurology, particularly
in dementia diagnosis.(173)
Computed tomography (CT) was the earliest neuroimaging technique used. However
further advances in neuroimaging techniques have led to more powerful techniques using
structural magnetic resonance imaging (sMRI), functional MRI (fMRI) and positron emission
tomography (PET).(174-176) These advanced techniques now allow detailed imaging of brain
structures, providing powerful techniques to track abnormal neurological developments in the
brain.(174)
While every neurodegenerative disease has specific areas in the brain that are affected,
some areas of interest for neuroimaging investigation of dementia are volumetric measures to the
total brain, entorhinal cortex, hippocampus, and amygdala, as well as white matter
hyperintensities.(177-181) The following sections will discuss evaluation of these sections of the
brain through structural MRI.
Brain volume measures through MRI to evaluate dementia
Structural MRI measures play an important role in investigating neurodegenerative
diseases such as dementia by allowing us to study the neuropathological changes without relying
solely on brain autopsies. Brain atrophy measures, via sMRI, is considered a valid biomarker for
Alzheimer’s disease (AD) progression.(182, 183)
Volumetric measures from sMRI are linked with pathological AD changes.(184-186)
Studies also show that MRI findings in AD patients are correlated with neuropathological
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changes that are found during autopsies.(187) Structural scans allow the assessment of
volumetric changes in the brain. This is particularly important in the investigation of
neurodegenerative diseases such as dementia, which can structurally appear as increased sulcal
size and decreased gyral size.(188)
Brain atrophy rates are also correlated with cognitive decline, assessed through
neuropsychological tests.(179, 189) In early neuroimaging studies, volumetric measures were
usually obtained manually. However, with further advances in neuroimaging techniques, postprocessing techniques in sMRI have made it possible to obtain automated volumetric
measures.(189, 190)
Total brain volume
Past studies have established that the change in total brain volume is a function of aging,
with the rate of decrease increasing in old age.(191) Global volume loss of the brain has also
been reported in early stages of cognitive impairment, suggesting that brain tissue damage is
widespread even in mild cognitive impairment.(192-196)
This loss is even more pronounced in advanced stages of dementia, suggesting that
progression of the disease involves global brain atrophy.(189, 192, 197-199) This is supported by
multiple longitudinal studies showing that total brain volume loss predicts the course of disease
progression in patients with mild cognitive impairment. (200-202) Total brain atrophy also
accelerates with the progression of cognitive decline.(178)

30

Hippocampal volume
One region of the brain in particular, which is of interest in neuroimaging studies of
dementia is the hippocampus, which shows early signs of atrophy particularly in Alzheimer’s
disease (AD).(203) In AD, hippocampal atrophy starts almost 5 years prior to clinical diagnosis
of the disease, with volume decrease of almost 10% at least 3 years before clinical diagnosis is
possible.(204) Studies assessing the correlation between hippocampal volume and Braak
neurofibrillary stage, found a strong inverse correlation between Braak neurofibrillary stage and
mean left hippocampal volume, both measured after death,(187) as well as a significant
correlation between hippocampal volume (determined at an average 1.8 years prior to death) and
Braak neurofibrillary stage.(205)
In their study on 32 non-demented nuns at death, Gosche and colleagues were able to
show that the hippocampal volume predicted AD pathology with a sensitivity of 0.83 and a
specificity of 1.00.(206) These studies show the utility of using sMRI measures to study AD
pathology, especially in the early stages of the disease.
Entorhinal cortex volume
While hippocampal volume is widely used as an sMRI marker in AD studies, it is
however the transentorhinal/entorhinal cortex that first shows pathological changes in the
disease, compared to the hippocampus.(185, 206, 207) The neurofibrillary pathology of AD is
first seen in the transentorhinal cortex before it spreads to other areas of the brain. This has been
the basis of the Braak pathologic staging of AD, where stages 1 and 2 represent the pathological
changes mainly in the entorhinal/transentorhinal cortex with very little to no changes in the
hippocampus.(207)
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Several autopsy histopathological studies show the involvement of the entorhinal cortex
in the early stages of AD.(207, 208) In patients with mild dementia, studies demonstrate that the
pathology in the hippocampus is significantly less compared to that in the entorhinal cortex.(208211) Therefore based on the biology of the AD pathology, the earliest detection of pathological
changes will be reflected in changes in the entorhinal cortex volume instead of the hippocampal
volume, making neuroimaging of the former an important component of the evaluation for
dementia.
However, there are some difficulties when it comes to measuring the entorhinal cortex
volume on structural MRI. This is because of the difficulty in visualizing the anatomical borders
of the entorhinal cortex on MRIs.(212) One study comparing MRI measures of hippocampal
volume and entorhinal cortex volume, found that anatomic ambiguity, in the lateral boundary of
the entorhinal cortex, a particularly difficult structure to identify, making it difficult to accurately
measure the entorhinal cortex volume. However, anatomic ambiguity was not a problem in the
measurement of hippocampal volume in this study.(213)
Amygdala volume
While hippocampal atrophy has been widely reported to be associated with AD, in early
stages of the disease, atrophy of the amygdala is just as severe.(214) Structural MRI studies have
found the involvement of the amygdala in early-onset AD.(180) Baseline volume of the
amygdala is a predictor in the conversion of mild cognitive impairment to AD, independent of
atrophy in other regions of the brain.(215) This supports the theory that a smaller amygdala
predicts conversion to AD. Atrophy of the amygdala is also present in patients with progressive
MCI compared to stable MCI.(216)
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Amygdala atrophy is also strongly associated with cognitive decline.(217) Compared to
lesions in the hippocampus alone, hippocampal-amygdala lesions result in greater memory
impairment.(218) The structural changes to the amygdala and its association with dementia is not
surprising. This is because the amygdala interacts with the hippocampal system, which is
associated with cognitive decline.(219) It may also compensate for the functional decline due to
atrophy of the hippocampus.(220)
White matter integrity measures through MRI
Postmortem investigations of the brain show that white-matter loss is related to aging
and occurs throughout the brain. Age related white matter loss is also more extensive compared
to gray matter loss.(221-224). Decrease in white matter integrity is correlated with cognitive
performance in the elderly, with stronger correlation with loss of white matter integrity in the
anterior regions of the brain.(181)
Diagnosis of vascular dementia (VD) includes a mandatory component of structural
neuroimaging, as the most common cause of VD is small vessel disease.(224) Signs of small
vessel disease, presented through white matter lesions, can be detected through MRI as white
matter hyperintensities (WMH).(224) This is because, small vessel disease can lead to white
matter infarcts the appear as white matter hyperintensities, allowing us to assess the extent of the
disease via sMRI imaging.(225)
Multiple studies have established the association between cerebral white mater lesions
and cognitive impairment.(226-229) White matter lesions are also associated with speed of
cognitive processes.(230, 231) Decline in white matter integrity in the frontal lobe is associated
with decline in reasoning(232) and memory.(233)
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Advantages and limitations of neuroimaging techniques in dementia studies
Based on the discussion above, we can establish the role of sMRI evaluations in
studies investigating cognitive impairment. Neuroimaging techniques do have some advantages
over neuropsychological assessments. Firstly, unlike neuropsychology tests, neuroimaging
studies are not affected by behavioral response of the individual. When done concurrently with
neuropsychology assessments, neuroimaging assessment can provide additional information,
particularly on the neural basis of the cognitive impairment and the pathological etiology of the
neurodegenerative disorder.(174) Neuroimaging techniques also have a unique clinical utility,
allowing us to assess the effect of interventions such as potential disease modifying medications
on brain atrophy rates.(234) While neuropsychology battery assessments can examine the
function of the different regions of the brain, through neuroimaging alone, we are still unable to
demonstrate the domain specific cognitive impairment based on the neuropathologies.(174)
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CHAPTER 4
MEDICATIONS IN THE OLDER ADULT POPULATION
This chapter briefly introduces issues related with medication use in the older adult
population, with a focus on inappropriate prescription and polypharmacy. It also presents the
specific problem of anticholinergics and opioids in the older population. This section will also
discuss the assessment of the anticholinergic burden of medications.
INAPPROPRIATE MEDICATION PRESCRIBING IN THE ELDERLY
Multiple comorbidities, such as hypertension, diabetes mellitus and heart disease, which
require pharmaceutical intervention, are common in the elderly.(235) Studies have reported that
compared to younger individuals, elderly individuals receive a disproportionately large number
of medications.(236, 237)
Inappropriate prescribing for the elderly includes polypharmacy, prescribing of
inappropriate medications or at inappropriate doses and under prescribing of medications.(238)
Evidence indicates that inappropriate prescribing in this vulnerable population happens both in
the community setting as well as among inpatients.(239-242) Polypharmacy in the elderly is
linked to an increase in the risk of adverse drug events. It is reported that compared to
individuals taking two medications at a time, the risk of adverse drug interactions increases by
69% in those taking 7 drugs or more at a time.(243)
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Among elderly patients, adverse drug events are linked to approximately 30% of hospital
admissions.(244) Adverse drug events in this population are also associated with preventable but
serious conditions such as falls, depression and confusion.(245) Among the older nursing home
residents, 1 in 7 adverse drug events are serious enough to warrant hospitalization.(246)
Medication related complications, if categorized as a cause of death, is reported to be the fifth
leading cause of death in the US.(247) These factors point to the severity of adverse drug events
in the elderly population.
Identifying and treating adverse drug events in the elderly is challenging. In this group,
adverse drug events often present as non-specific symptoms often mistaken as part of aging, such
as lethargy, falls and constipation.(244) When unrecognized, symptoms of adverse drug events
are treated with more medications.(248) This leads to the importance of understanding the effect
of certain medication groups in the elderly population to inform better prescribing of
pharmaceutical interventions in this population.
ANTICHOLINERGICS AND COGNITION
Medications with anticholinergic properties are an integral part of pharmaceutical
intervention for multiple common ailments, from asthma to urinary incontinence.(249) These
medications have been known to have adverse effects, ranging from peripheral effects such as
dry mouth to central nervous system effects as serious as hallucinations. The elderly are
particularly susceptible to anticholinergic adverse effects due to age related changes such as a
decrease in cholinergic neurons, reduced liver and kidney functions, and a more permeable blood
brain barrier.(250)
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Cholinergic system
Cholinergic neurons and their corresponding receptors are located in the peripheral and
central nervous systems. Most of the cholinergic neurons in the central nervous system (CNS)
are in the basal forebrain and the midbrain. From these brain regions, the cholinergic input is
projected to other regions of the brain and CNS, including regions of the cerebral cortex, the
hippocampus and the amygdala.(251-253)
In the brain, cholinergic neurons produce Acetylcholine (ACh), through the action of
choline acetyltransferase (CAT). CAT, a synthetic enzyme, combines co-factor coenzyme A and
choline, which results in the production of ACh. Acetylcholine (ACh), a neurotransmitter, is
distributed throughout the nervous system. It binds to nicotinic receptors and muscarinic
receptors, both receptors that play a role in memory and learning processes. ACh is hydrolyzed
by Acetylcholinesterase (AChE).(254-258)
ACh, through the parasympathetic response, plays a vital role in multiple activities such
as the development of the cerebral cortex, modulating cortical activity and cerebral blood flow,
and controlling cognitive processes. Anticholinergic drugs disrupt the cholinergic system by
binding to receptors at parasympathetic nerve endings, providing fewer available receptors for
ACh and thus reducing parasympathetic responses.(259)
The cholinergic neurons have been found to degenerate as we age.(260) However, the
theory of wide neuronal loss in normal aging has been challenged.(261) Instead, neuronal cell
loss is reported in pathological aging, particularly in neurodegenerative diseases such as
AD.(262) The basal forebrain cholinergic system is particularly vulnerable in such diseases.(263)
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Effect of anticholinergics on cognition
Every year, approximately 6.8 million ambulatory care visits are made in the United
States due to dementia. Of these, almost 43% include patients on at least one medications with
anticholinergic property.(264) This is concerning as studies have shown the association between
anticholinergic use and adverse effect on cognitive function in the elderly. This association has
been found in both older adults living in the community as well as in residential care.(265-267)
Compared to older adults not on anticholinergics, older adults on anticholinergics had a higher
incidence of cognitive impairment, AD and dementia.(268, 269)
Studies have also shown that use of anticholinergics are linked to impairment in
multiple cognitive domains. These include cognitive domains such as attention, processing
speed, psychomotor skills and language skills.(154, 155, 249, 269, 270) Evidence also indicate
that the rate of decline accelerates with long-term use of these medications.(271)
Sustained long-term use of anticholinergic medications is shown to be linked with the
acceleration of AD pathology.(272) In AD patients, the cholinergic system is particularly
affected by the disease. Autopsy brain investigations of individuals with AD has shown
compromised ACh receptor binding activity and reduced ACh.(273, 274) AD patients were also
found to have fewer cholinergic cells in their forebrain, pointing to cholinergic loss in the
disease.(275) However, the effect of anticholinergics on global cognitions has been mixed.(272,
276)
The “Cholinergic hypothesis of geriatric memory dysfunction” was developed after
the association between age-related memory impairment and cholinergic dysfunction was
established.(277) This theory hypothesizes that cognitive impairment due to AD is a result of
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decline in the cholinergic neurotransmission in the basal forebrain.(278) It is further supported
by evidence of cognitive function improvement in patients receiving medications that improve
central cholinergic function.(279)
Assessing anticholinergic burden
Anticholinergic burden is defined as the cumulative effect of taking medicines with
anticholinergic properties.(280) One of the challenges in evaluating the adverse effects of
medications with anticholinergic properties is the difficulty in assessing and quantifying the
anticholinergic burden of medications. This is mainly due to the challenges in developing a
uniform method to assess anticholinergic burden that would not require extensive training and
resources to use. Several methods have been introduced to assess anticholinergic activities due to
medications.
One of the most straightforward method in assessing anticholinergic activities due to
medications is by assessing drug lists of medications with anticholinergic properties and
combining it with clinical judgement. This method elicits a clinical judgement of anticholinergic
activity of medications in a reference list.(281, 282) This method has led to the development of
multiple drug scoring scales. Another approach is to measure anticholinergic activity of
individual drugs, using a radio receptor assay method that compares the anticholinergic property
of a drug to a highly anticholinergic drug, atropine.(20)
Anticholinergic burden of a medication can also be assessed by measuring the total serum
anticholinergic activity from a drug, its metabolites and an individual’s physiology.(28) This
method is considered the gold standard to quantify the anticholinergic burden of a drug.(283) The
anticholinergic burden of a drug can also be evaluated by measuring the drug’s affinity to
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muscarinic receptors, which done in vitro, informs us of the drug’s anticholinergic activity.(284,
285) In all the methods discussed above, none, individually, are able to measure all the
characteristics of anticholinergic activity due to medications.
Assessing anticholinergic burden using standardized drug scales
Through the use of standardized drug scales, the concept of assessing anticholinergic
burden from a list of known drugs and clinical judgement can be objectively done. This method
is also reported to be clinically applicable in studies evaluating cognitive effects of medications
with anticholinergic properties.(286) This led to the development of rating scales, which have
been used in both research and clinical settings. These tools, through expert opinion, rank the
anticholinergic burden of medications into categories, often ranging from no anticholinergic
activity noted to high anticholinergic activity.(283, 287-290)
Although multiple tools exist, four distinct assessment instruments that have been
developed for this purpose are: The Anticholinergic Drug Scale (ADS)(283), The Drug Burden
Index (DBI),(288) The Anticholinergic Risk Scale (ARS)(289), and The Anticholinergic Burden
(ACB) score.(291) Compared to the other scales, the ADS is the only instrument to have been
validated against the serum anticholinergic activity test, which is the gold standard in the
assessment of anticholinergic burden. ADS also includes a thorough and extensive list of
anticholinergic medications, both prescription medications and over the counter
medications.(283) Between the scales, a significant variability of anticholinergic burden
quantification exists, mainly due to the subjective rating of anticholinergic burden in the
individual expert panels.(292)
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While the serum anticholinergic assay method is considered the gold standard, the
assessment of anticholinergic burden using standardized drug scales has its own unique utility
advantages. These scales are relatively easy to use and are cost effective. This method is
however affected by prescribing records and/or self-report, which have their own inherent
methodological biases.
OPIOIDS IN THE OLDER ADULT POPULATION
Pain in the elderly
Evidence indicates that most elderly individuals experience some level of pain on a day
to day basis, with some experiencing significant pain that interferes with their normal
functioning.(293) There is compelling evidence that indicates an age-related increase in the
prevalence of chronic pain.(294-296) This age-related increase is not limited to just joint pain, as
commonly expected in the elderly population.(297) The most common causes of chronic pain in
this population is arthritis and neuralgias.(33)
Chronic pain complaints are higher among elderly individuals living in the community
compared to those in an institutionalized setting.(298, 299) Chronic pain is associated with poor
daily functioning, affected mood and withdrawal from recreational activities.(300, 301) There is
a possibility that prevalence of chronic pain in the elderly is severely under-reported. This may
be due to several factors. A lower prevalence of chronic pain among community-dwelling older
adults may be due to increasing mortality rate with age and institutionalization of elderly patient
with severe chronic pain complaints.(302) Also, there may be differences in personal
interpretation of pain in aging, which can influence the reporting of chronic pain.(303)
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With the increase in the prevalence of chronic pain in the elderly, the use of opioids for
pain management in this population has increased markedly.(304-306) Commonly used opiates
are combination opiates (that contain oxycodone, hydrocodone with acetaminophen or other
NSAIDs) and short acting opiates such as oral morphine, oxycodone and codeine. Opioids
generally have peak analgesic effects within 60 minutes of administration and are dosed at 4hour or 6-hour intervals.(307)
Aging and opioid pharmacology
As we age, several factors affect the way our bodies handle pharmacological
interventions. Significant factors that affect this mechanism are age-related changes in functional
organ capacity, and the pharmacokinetics and pharmacodynamics.(235, 308) These factors
contribute to the unique challenges in the use of pharmacological agents to control pain in the
elderly.
Aging results in a progressive loss of organ function, particularly the liver and kidney,
which are key organs in drug metabolism. This leads to reduction in optimal handling and
excretion of pharmacological agents. Additionally, aging also changes body composition in
terms of a decrease in water content in the body, increase in body fat content and changes in
protein binding mechanisms.(308) An age-related decrease in the intake, absorption and
processing of substrates affect pharmacodynamics in the elderly. Receptor responses also
decrease with age, due to the decrease in the production of neuropeptides and neurotransmitters,
decrease in the number of receptors and an overall decrease in receptor affinity. Evidence also
indicates that reduced drug clearance is observed in older adults administered morphine for pain
control.(308)
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Pharmacological intervention for pain in older adults must be approached with caution.
The geriatric population is considered a challenging population to treat for pain because of
multiple issues related to existing comorbidities, age related increase in the risk of cognitive
impairment and inherent polypharmacy in the elderly.(309) Treatment for pain in the elderly
must be in line with the World Health Organization (WHO) analgesic stepladder, which uses
pain severity measures to categorize the intensity of pain and recommends the appropriate
analgesic to be used.(310)
Opioids and pain pathways
Chronic pain can either be nociceptive pain, due to damaged tissues or neuropathic pain
due to nerve damage.(311) Opioids are used to manage nociceptive pain. Nociceptors, or free
nerve endings, can be found in somatic and visceral tissues. There are unique nociceptors that
respond to physical, chemical and thermal noxious stimuli. When stimulated, pain is transmitted
from the site of origin to the brain for pain perception. Acute pain is primarily transmitted in the
pain pathway by A-delta afferent sensory nerve fibers. Chronic pain on the other hand, is
primarily transmitted by unmyelinated C sensory afferent nerve fibers.(312)
The opioid system not only controls pain, but it also controls the reward and addictive
behavior system. Opioids act through 3 distinct opioid receptors, the mu, delta and kappa
receptors. Opioid receptors are found in the nervous system, in regions for pain transmission. In
the brain, opioid receptors are activated by endogenous peptides (enkephalins, dynorphins and
endorphins). They can also be activated by exogenous agents, such as alkaloid opiates.(313)
Studies show that naturally occurring opioid peptide, b endorphin, interreacts with mu
receptors preferentially, while enkephalins prefer the delta receptors and dynorphin the kappa
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receptors. Morphine preferentially interacts with mu receptors. All three of these receptors
produce analgesic effects when bound to an opioid.(314)
Opioid drugs act on several levels of the nervous system to produce their analgesic
effect. Opioids produce central analgesic effects as well as peripheral analgesic effects.(315)
Peripheral opioid receptors respond to both endogenous and exogenous opioids. Peripherally,
opioids suppress the activity of nociceptors to provide pain relief. Opioids also produce pain
relief at the spinal cord level. When opioids are administered directly to the spinal cord, they
block the response to pain stimulation.(316)
Chronic exposure to opioids can introduce tolerance and more seriously, dependence to
the drugs.(314) Tolerance is a result of a desensitization mechanism and will result in the need
for higher doses to produce the desired effect. This is particularly dangerous in the elderly, due to
dose-response related adverse events. The effect of dependence is only seen when abstinence
from opioids occurs or if an opioid receptor antagonist is administered. Dependence also occurs
much faster than tolerance for opioids.(314)
Effect of opioids on cognition
Multiple side effects have been reported to be associated with opioid use in older
adults. These include adverse effects such as nausea, constipation, urinary retention, sedation and
dizziness.(307, 317, 318) The development of adverse events is associated with factors such as
advanced age, existing comorbidities and predisposed genetic differences among individuals.
Additionally, impaired kidney and liver function also increases the risk of developing adverse
events due to opioid intake.(309) In older adults, a side effect of concern is the adverse effect of
long term opioid use on cognition.
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Opioids are associated with delirium, particularly in post-operative patients. In a
study on older patients in the intensive care unit (ICU) setting, opioids were associated with
prolonged episodes of delirium. This association remained even after adjustment for other
delirium risk factors such as illness severity and existing cognitive impairment.(319)
Opioids also provoke cognitive impairment and hallucinations in the elderly.(320, 321)
These effects are usually augmented by factors such as increasing the dose of the opioid
administered and changing the route of administration from oral to intravenous. A common side
effect of opioids is sedation which may explain psychomotor impairment.(322) Evidence also
indicates that opioids influence learning and memory. (323) Opioids block pain sensation by
disrupting normal neurotransmitter activity in the brain, which could lead to these impairments.
These findings indicate the importance of further establishing the effect of opioids on the
different cognitive domains.
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CHAPTER 5
METHODS
This chapter discusses the methodology used to address the specific aims of this
dissertation. Brief descriptions of these methods were included in the manuscripts prepared for
this dissertation.
PATH Through Life Study
The Personality and Total Health (PATH) Through Life Study is an ongoing longitudinal
cohort study that assesses the lifespan course of multiple diseases and wellbeing among
community dwelling Australian adults. The original aims of this population based study
are:(324) “
i.

To delineate the course of depression, anxiety, substance use and cognitive ability
with increasing age across the adult life span

ii.

To identify environmental and genetic risk factors influencing individual differences
in the course of these characteristics

iii.

To investigate inter-relationships over time between the three domains of depression
and anxiety, substance use and cognitive ability and dementia.”

To date, the PATH study has followed three cohorts of participants starting at ages 20 to 26
years, 40 to 46 years and 60 to 66 years for approximately 20 years. The study participants are
from three narrow age cohorts with birth years of 1975-79 (the 20+ cohort), 1956-60 (the 40+
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cohort) and 1937-41 (the 60+ cohort) respectively. Participants of all three cohorts were
randomly sampled from the electoral rolls of the Australian Capital Territory (ACT) and
Queanbeyan, Australia. Electoral rolls of the three federal electorates of ACT and the electorate
of Eden-Monaro (of which only those of Queanbeyan residents were selected) were used to draw
the study sample.
Wave 1 of the PATH study began between the years 2000 and 2002, and the three cohorts
were followed at 4-year intervals, with each cohort, starting with the youngest cohort, being
interviewed successively over a one-year period. (as shown in Figure 3). Participation rates for
follow-up visits across the cohorts range from 89% to 93%. Three sub-studies derived from
subsamples of the main PATH study have been done. These studies are the Magnetic Resonance
Imaging (MRI) study, the Health and Memory study and the Cardiovascular study.
Study population
The study population for this dissertation will be the 60+ cohort in the PATH study. Analysis
for the first aim in this dissertation utilized data from the first follow-up wave (Wave 2, year
2005 / 2006, n = 2222) to the third follow-up wave (Wave 4, year 2014 / 2015, n=1645). The
remaining of the analysis utilized data from Wave 2 to Wave 3 (year 2009/2010, n=1973).
Additionally, data from the MRI sub-study from Wave 2 (n=374) to Wave 3 (n=325) were used.
Exposure Measurement
The exposure of interest in this dissertation is use of medications with anticholinergic
properties and opioids. Data on prescription medication use of all study participants was obtained
through the Pharmaceutical Benefit Scheme (PBS).
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Figure 3: Sample size, participation rate and retainment rate of the PATH Through Life
study by cohort and wave
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Pharmaceutical Benefit Scheme
The Pharmaceutical Benefit Scheme, established in 1948, is a list of medications that can
be dispensed to patients at a subsidized rate from the government of Australia. The initial PBS
listed 100 medications that were free to all. Over time, the list continues to grow to include
newer medications and medications on the list are no longer free. The Pharmaceutical Benefits
Advisory Committee (PBAC) reviews medicines to be listed in PBS and recommendations are
made to the Minister of Health, who then decides on the medicines that are included in the PBS
schedule list. This list is updated monthly to add newer medications, to remove medications and
to note changes to the medical conditions for which the subsidy should be applied to.
The PBS is managed by the Department of Health and it is administered by the
Department of Human Services. This service is available to all Australian residents with a
Medicare card and individuals visiting Australia from countries that have a reciprocal healthcare
agreement with Australia. All citizens and individuals with permanent resident status in Australia
are entitled to a Medicare card.
Eligible patients pay a nominal co-payment for their PBS medications, with the
remaining cost of the medications being paid by the Australian government. Detailed explanation
on the PBS and its use in pharmaco-epidemiology research is explained elsewhere.(325, 326)
Data extraction from the PBS data
From Wave 2, the medication use of participants of the PATH study was obtained
through data linkage to the main PBS database. For this dissertation, information on medications
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with anticholinergic properties and opioids were obtained from the medication data of the PATH
study.
To extract information on these medications a list of medications with anticholinergic use
and opioids was made with the corresponding Anatomical Therapeutic Chemical (ATC)
Classification System code. This coding system, controlled by the World Health Organization
Collaborating Centre for Drug Statistics Methodology, classifies drugs according to the body
system they act on, the therapeutic nature of the drug, and the chemical characteristics of the
drug.(327) The ATC codes for medications of interest in this dissertation was then used to match
and extract medications on the participant specific medication use data from the PATH study.
The PATH medication use dataset also includes the variable ‘PBS item code’. When the
medication dataset had missing ATC codes, the PBS item code was used for data extraction. To
do this, the list of PBS item codes that correspond to the list of ATC codes was prepared by
using the PBS item code search on the main PBS website.
Medications with anticholinergic properties
Medication rating scales are commonly used, both in clinical settings and research
studies, to assess anticholinergic burden. In this dissertation, medications with anticholinergic
properties were be identified using the Anticholinergic Risk Scale (ARS)(289) and the
Anticholinergic Drug Scale (ADS)(283).
In the ARS, medications are classified as having limited or no anticholinergic potential
(rated 0), moderate anticholinergic potential (rated 1), strong anticholinergic potential (rated 2)
or very strong anticholinergic potential (rated 3). In the ADS, medications are classified as
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having potential anticholinergic potential (rated 1), moderate anticholinergic potential (rated 2)
and marked anticholinergic potential (rated 3). For this dissertation, medications rated 1 on the
ADS and 0 on the ARS were excluded. Medications not on either of the scale but classified as
highly anticholinergic in the American Geriatrics Society 2012 Beers Criteria for potentially
inappropriate medication use in older adults were included. A table of corresponding ATC codes
for the medications included was made and used for data extraction from the parent medication
dataset of the PATH study.
Exposure measure for medications with anticholinergic properties was the cumulative
total standardized daily dose (TSDD), as used in past studies.(328) To derive the TSDD, first the
total dose of medications with anticholinergic properties in each prescription was calculated by
multiplying medication strength with number of tablets. This value was then divided by the
medication specific recommended minimum effective daily dose per day to derive the
standardized daily dose (SDD).(329) SDD for all medications was summed during the exposure
period to derive the cumulative total SDD (TSDD). Figure 4 shows an example for calculating
TSDD.(328)
Opioids
For this dissertation, medications classified as opioids in the WHO ATC Classification
were included. Exposure to opioids was quantified using the total morphine equivalent dose
(MED). MED for each opioid prescribed during the study period was derived by first computing
the product of the quantity of opioids in a prescription by their respective strengths. This product
was then multiplied with morphine conversion factors. (330-332). The MEDs during the study
period was then summed to obtain the Total MED for each study participant.
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Figure 4: Example of the total standardized daily dose (TSDD) calculation (328)
Reprinted from JAMA Internal Medicine 175/3, Gray et al, “Cumulative Use of Strong
Anticholinergics and Incident Dementia: A Prospective Cohort Study”, Copyright 2015, with
permission from American Medical Association
Outcome Measurement
Cognitive Function
Cognitive function of the PATH study participants was assessed through a
comprehensive neuropsychological test at each study wave. Tests were administered by trained
interviewers, who received a week-long training before the start of Wave 1 data collection,
which included training on administration of the cognitive tests. Regular meetings were held
with interviewers to discuss and resolve methodological issues that arise during data collection.
Interviews were conducted at participants’ homes or place of work.
The neuropsychological battery targets a broad range of cognitive domains that affect the
overall cognitive function of the participants. The cognitive domains and respective
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neuropsychology testing information from the PATH study which were used in this dissertation
is summarized in Table 4.
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Table 4: Details of cognitive assessment measures
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Brain volume measures
A sub-sample of the PATH study participants were randomly selected at Wave 1 to form
the MRI sub-study population. Identified participants were invited to participate in the MRI substudy and interested participants were then screened to ensure suitability to undergo MRI
investigation. MRI data were obtained using a 1.5 Tesla Gyroscan scanner. T1-weighted 3D
structural images were done in coronal plane using the Fast Field Echo (FFE) sequence. To
obtain volumetric measures of brain structures, volumetric segmentation was done using the
Freesurfer image analysis suite. Detailed description of the methods to obtain volumetric
measures of brain structures in the PATH Through Life study is explained elsewhere.(333) All
MRIs were conducted at National Capital Diagnostic Imaging (NCDI) and MRI data were stored
digitally. For this dissertation, measures of total brain volume, bilateral hippocampal volume,
bilateral entorhinal cortex volume, bilateral amygdala volume and white matter hypo-intensities
were used.
Covariates
Based on past studies, several covariates found to be associated with anticholinergics and
opioid use, and cognitive impairment were included in this dissertation. These include
demographic variables such as age, sex, and years of education. Covariates representing clinical
risk factors include information on stroke (self-reported), diabetes (self-reported), hypertension
(defined as systolic blood pressure ≥ 140mmHg, diastolic blood pressure ≥ 90mmHg or selfreported use of antihypertensives), body mass index (BMI) (computed as weight (kg)/ height
(m)2), family history of dementia and depression (assessed with Patient Health Questionnaire
(PHQ-9)).(334). Covariates representing lifestyle related risk factors were also included.
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Smoking status was obtained from a self-reported questionnaire (and coded as current smoker,
past smoker and never smoked). Self-reported physical activity, assessed as hours of mild,
moderate and vigorous activity per week, and alcohol consumption, assessed as number of drinks
per week, were also included. For assessment of effect modification, the apolipoprotein E
(APOE) epsilon 4 (ε4) genotype was included as a covariate of interest. Genotyping for APOE
variants in the PATH study population has been described elsewhere.(335)
Statistical Analysis
This section briefly describes the statistical analyses used to address the study aims. All
statistical analyses will be completed using SAS (version 9.4, SAS Institute Inc., Cary, North
Carolina), SPSS (version 25, IBM Corp., NY) and Joinpoint Regression Program (v. 4.5.0.1,
Statistical Methodology and Applications Branch, Surveillance Research Program). Detailed
analyses of the individual manuscripts are explained in their respective chapters.
Aim1: Describe the prescribing trend of medications with anticholinergic properties and opioids
among individuals aged 60 and above.
Descriptive analysis was done to describe the study population at baseline (Wave 2). The
proportion of the different types of medications with anticholinergic properties prescribed during
the study duration were generated to understand which medication groups were prescribed most
frequently during the study period. A Joinpoint regression model was used to investigate the
temporal prescription trend of medications with anticholinergic properties and opioids from 2004
to 2015 in the study population. Significance of the trend was assessed using a Monte Carlo
permutation method.(336) Annual percent change (APC) in the proportion of prescriptions for
each trend and the corresponding 95% confidence interval will be estimated. The APC of
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individual trend lines were tested against a null hypothesis of no change (APC=0%). The
prescription trend for medications with anticholinergic properties was further stratified by the
anticholinergic burden level (moderately anticholinergic and highly anticholinergic).
Aims 2, 3, 4 & 5: Examine the association between the use of anticholinergics and opioids
among individuals aged 60 and above, and subsequent change in cognitive function and brain
volume.
Bivariate analysis was done to describe the study population at baseline (Wave 2) based on
exposure status. Generalized Linear Models (GLM) were used to assess the association between
medications with anticholinergic properties and opioids and change in cognitive function and brain
volume (from Wave 2 to Wave 4), and the effect modification of this association by APOE-ε4
allele. Three statistical models were used to assess these associations; An unadjusted model
(Model), a partially adjusted model for age, sex and years of education (Model 2), and a fully
adjusted model with all covariates (Model 3). To minimize Type 1 error due to multiple
comparisons, statistical significance was maintained at 0.01.
Funding and Ethics Approval
The PATH Through Life Study is funded by the National Health and Medical Research
Council (NHMRC) grants 179805 and 1002160, and 418039. The use of the PATH Through Life
Study for this dissertation was funded by the Endevour Research Fellowship.
The PATH Through Life Study was approved by the Australian National University Ethics
Committee. All study participants provided written informed consent to participate in the PATH
study and to have their data linked to the Pharmaceutical Benefits Scheme (PBS) data. This
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dissertation analyses using the PATH Through Life study was exempted from review by the
University of South Florida’s Institutional Review Board. (Appendix A)
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CHAPTER 6
MANUSCRIPT 1: Trends in Anticholinergic and Opioid Prescription in the Older Adults
from 2004 to 2015. Results from the Personality and Total Health (PATH) Through Life
Study.
ABSTRACT
Due to their adverse effects on cognition, current guidelines recommend that medications
with anticholinergic properties and opioids be avoided in the elderly unless medically necessary.
This study examines the temporal prescription trend in the use of these medications in an elderly
population. Study population consisted of 2222 individuals age 60 years and older at baseline
from the PATH Through Life Study in Australia. Medication data were obtained from the
Pharmaceutical Benefits Scheme (PBS) from April 2004 to March 2015. Temporal trends of
prescriptions were assessed using joinpoint regression analysis. Baseline characteristic were:
mean age of 66.6 ± 1.5 years, 51.6% male and mean years of education 13.9 ± 2.6 years. During
the study period, 5.5% of all prescriptions were for anticholinergics and opioids, and 46.2% of
anticholinergics prescribed were anti-depressants. Overall, the trend for prescribing medications
with anticholinergic properties increased in 2004 – 2015 (annual percent change, APC = 3.4%).
This increase was also observed for moderately anticholinergic medications (APC=6.8%). The
prescribing trend for opioids increased in 2004 – 2011 (APC = 11.3%) and declined in 2011 –
2015 (APC= -4.4%). While guidelines urge caution in prescribing these medications to the
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elderly, prescribing increased over time in this study population. Examining trends in
prescribing patterns over time may inform educational messages for both patients and providers.
INTRODUCTION
Approximately 90% of individuals aged 65 years and above are prescribed at least one
medication, of which 50% receive a prescription for five medications or more.(1, 2) Prevalence
of inappropriate prescribing is high in community dwelling older adults, and is associated with
an elevated risk of morbidity and mortality.(248)
Multiple chronic conditions, which are common in the elderly, may be treated with
medications exerting anticholinergic properties such as antihypertensives, skeletal muscle
relaxants, and antiarrhythmic drugs.(249) Although guidelines have cautioned that the risk of
anticholinergic use exceeds the benefits in the elderly (249) the prevalence of use of medications
with anticholinergic properties in this vulnerable population still ranges from 8% to 37%.(9, 269)
In older adults, the prevalence of opioid use has increased significantly over the
years.(10, 305) This can be attributed to an increase in chronic pain associated with aging, (33)
greater awareness and attention to pain management and newer opioid medications with fewer
adverse effects.(34, 35)
This study aims to examine the temporal trends in prescribing of these medications in an
elderly population in Australia over a period of 11 years.
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METHODS:
The PATH Through Life study is an ongoing, population-based longitudinal study that
aims to track the course of multiple diseases across the lifespan. Three cohorts with birth years
1975-79, 1956-60 and 1937-41, with a total of 7,485 adults, were randomly sampled from the
electoral roll of the Australian Capital Territory and Queanbeyan, Australia. The cohorts were
followed at 4-year intervals, with Wave 1 starting between the years 2000 to 2002. The design of
the PATH study has been previously described.(324) This analysis focuses on the oldest cohort
of the PATH Through Life study, from the first follow-up wave (Wave 2, year 2005/2006,
n=2222) to the third follow-up wave (Wave 4, year 2013/2015, n=1645).
Prescription medication information from the Pharmaceutical Benefits Scheme (PBS)
was obtained from April 2004 to March 2015 for all participants. Medications with
anticholinergic properties were identified using the Anticholinergic Risk Scale (ARS)(289) and
the Anticholinergic Drug Scale (ADS).(283) In the ARS, medications are classified as having
limited or no anticholinergic potential (rated 0), moderate anticholinergic potential (rated 1),
strong anticholinergic potential (rated 2) or very strong anticholinergic potential (rated 3). In the
ADS, medications are classified as having potential anticholinergic potential (rated 1), moderate
anticholinergic potential (rated 2) and marked anticholinergic potential (rated 3). Medications
rated 1 on the ADS and 0 on the ARS, considered not to have significant anticholinergic
properties, were excluded. In the event a medication was rated differently on the two scales, the
higher rating was used.(337) Medications not on either of the scales but classified as highly
anticholinergic by the American Geriatrics Society 2012, updated Beers Criteria (4) for
potentially inappropriate medication use in older adults, were included in this study. Opioids
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were classified according to the World Health Organization’s Anatomical Therapeutic Chemical
(ATC) classifications.
Descriptive analysis was conducted to understand the study population characteristics.
Joinpoint regression analysis (336) was used to investigate the temporal trends in prescriptions
for medications with anticholinergic properties and opioids between April 2004 to March 2015.
Joinpoint regression determines changes in the trend in terms of the rate of change and direction
over time. These changes in the trend are described through the connection of trend segments at
“joinpoints”. Significance for trend was assessed using a Monte Carlo permutation method.
Annual percent change (APC) in the proportion of prescriptions for each trend and the
corresponding 95% confidence interval were also estimated. All statistical analyses were
completed using SAS (v.9.4, SAS Institute Inc., Cary, North Carolina) and the Joinpoint
Regression Program (v. 4.5.0.1, Statistical Methodology and Applications Branch, Surveillance
Research Program). Additionally, the prescription trend was stratified by the anticholinergic
burden level (moderately anticholinergic and highly anticholinergic).
RESULTS:
During the study period, 5.5% of all prescriptions supplied were for medications with
anticholinergic properties and opioids. Baseline characteristics of the study population were:
mean age 66.6 ± 1.5 years, 51.6% male, 96.1% white, mean years of education 13.9 ± 2.6 years.
(Table 5 ) Of the 2,222 study participants, 18.9% had used medication with anticholinergic
properties for at least 30 continuous days. The most commonly prescribed medications with
anticholinergic properties were anti-depressants (46.2%). (Table 6)
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Figures 5, 6 and 7 depict the prescription trend of medications with anticholinergic
properties and opioids from 2004 to 2015. The APC of the proportion of prescriptions for
medications with anticholinergic properties increased by 3.4% (95% CI: 2.7-4.1) annually, with
no inflection points in the trend. The APC of the proportion of prescriptions for medications with
moderate anticholinergic activity increased by 6.8% (95% CI: 5.8-7.9) annually, with no
inflection points in the trend. However, no significant trend was observed for prescriptions for
medications that were highly anticholinergic. (Table 7)
During the study period, 687 individuals (30.9%) received a prescription for opioids. The
APC of the proportion of opioid prescriptions increased by 11.3% (95% CI: 6.7-16.0) annually
from 2004 to 2011. The best fit joinpoint regression model showed an inflection point in the
prescription trend for opioid in 2011. However, a significant trend was not noted from 2011 to
2015.
DISCUSSION:
This study investigated prescription trends of medication with anticholinergic properties
and opioids in sample of older adults in Australia. In this study, the prescription trend for
medications with anticholinergic properties increased at an APC rate of 3.4%. Similar increase in
anticholinergic prescribing trend in older adults has been reported in the UK.(338) While an
increase in the APC rate was observed for opioids between 2004 and 2011, this rate declined
from 2001 to 2015.
While the increase in prescribing medications with anticholinergic properties is small, it
is nevertheless a significant continuous increase over time. This suggests that the prescribing of
these medications has not decreased in the elderly study population as would be expected, given
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the existing cautions and guidelines. Common prescription of anti-depressants in this population
highlight the complexity of treating comorbidities in older adults. While the anticholinergic
properties of anti-depressants can contribute to cognitive impairment, untreated depression is
also an important risk factor for cognitive deficits. It appears that prescribing of opioids in this
elderly population, which decreased over the last few years, is approached with more caution.
However, it is unclear if specific policy interventions pertaining to opioid use was introduced
during the time of this infection point in the trend.
Medications with anticholinergic properties have side effects, particularly in the elderly,
ranging from peripheral effects such as constipation and dry mouth to central nervous system
effects including cognitive impairment.(16-19) Age increases permeability of the blood-brain
barrier, reduces the cholinergic receptors in the brain and changes the efficiency of hepatic and
renal function to metabolize these medications. These factors heighten sensitivity to
anticholinergics in the elderly, making them more susceptible to adverse effects.(249) The
adverse effects of high anticholinergic load become more profound among those with worsening
of cognitive function, particularly individuals with dementia, as they already have reduced levels
of acetylcholine.(339)
Similarly, multiple studies have reported the side effects of opioid use. Studies
demonstrate that prescription opioid use is associated with delirium(36) and may potentially be
linked to an increased risk of dementia.(340) Opioids also have lasting effects on the brain.(341)
Opioids modulate microglia behavior (37) and inflammation mediating immune response in the
brain,(38) and may be associated to neurodegenerative disease. This is further supported by
findings from autopsy examinations of young substance abusers that indicate neuropathological
changes similar to AD.(37, 39)
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The PATH Through Life study has several strengths, which include a large and randomly
selected population sample, narrow age cohort groups, and an ongoing longitudinal study design.
Data on medication use is uniquely difficult to obtain. However, in this study, we were able to
use an objective measure of prescription medication data, using the PBS data. This eliminated
the need to rely on self-reported medication use, which can be highly unreliable in the elderly,
particularly due to recall limitations.(342)
This analysis had some limitations. These include the high education level of the study
participants, possibly indicating better socio-economic status. While the PBS data captures
medications prescribed and dispensed, it does not provide information on medication adherence.
The PBS does not capture medications purchased privately and non-prescription medications. As
in most longitudinal studies, successive drop-outs were present at each study wave.
In summary, although medications with anticholinergic properties and opioids have
adverse effects on cognition, they were increasingly prescribed in Australia from 2004 to 2015.
This pattern has the potential to increase cognitive impairment in the community. Whilst this
finding needs to be replicated, it appears that there is an ongoing need for careful review of
guidelines for the prescribing of these medications for older adults.
CONCLUSION:
Medication requirements for older adults are complex and must be approached carefully
to avoid complications from medication related adverse events. Studies examining prescribing
trends of potentially inappropriate medications in the elderly help us understand the scope of the
problem in different settings. It improves our understanding of the successes and failures of
prescribing practices for the elderly and their guiding policies internationally. It ultimately leads
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us to better inform policies and implementation efforts on safe pharmaceutical use in the growing
elderly population.
Table 5: Baseline characteristics of study population: PATH Through Life Study (Wave 2)
2005-2006
Variable

Study population
(n= 2222)

Age (years), mean (SD)

66.6 (1.5)

Gender, n (%)
Male

1147 (51.6)

Female

1075 (48.4)

Years of Education, mean (SD)

13.9 (2.6)

Marital Status, n (%)
Married

1642 (73.9)

Unmarried-living with partner

76 (3.4)

Separated

45 (2.0)

Divorced

220 (9.9)

Widowed

188 (8.5)

Never married

50 (2.3)

Race, n (%)
White

2133 (96.1)

Asian

52 (2.3)

Other

35 (1.5)
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Table 6: Proportion of medications with anticholinergic properties prescribed from April
2004 to March 2015: PATH Through Life Study
Proportion of anticholinergic prescription,
Medication class

% (total number of prescription)
(n=11,235)

Anti-depressant

46.21 (5192)

Anti-Parkinson’s

19.15 (2152)

Medications for acid related

10.81 (1214)

disorders
Gastrointestinal medication /

8.81 (990)

antispasmodics
Bladder antimuscarinics

5.45 (612)

Atypical antipsychotics

3.64 (409)

Anti-epileptics

2.63 (295)

Muscle relaxant

2.00 (224)

Antiemetic/Antivertigo

1.14 (128)

Typical antipsychotics

0.10 (11)

Antihistamines

0.07 (8)
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^ Indicates that the Annual Percent Change (APC), from the final jointpoint model, is
significantly different from zero at the alpha of 0.05.
Figure 5: Prescription trend of medications with anticholinergic properties from 2004 to
2015: PATH Through Life Study
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^ Indicates that the Annual Percent Change (APC), from the final jointpoint model, is
significantly different from zero at the alpha of 0.05.
Figure 6: Prescription trend of medications with anticholinergic properties by
anticholinergic activity from 2004 to 2015: PATH Through Life Study
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^ Indicates that the Annual Percent Change (APC), from the final jointpoint model, is
significantly different from zero at the alpha of 0.05.
Figure 7: Prescription trend opioids from 2004 to 2015: PATH Through Life Study
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Table 7: Joinpoint analyses of prescription trends of medication with anticholinergic
properties and opioids from 2004 to 2015: PATH Through Life Study

Trend
Medications

Medications with
anticholinergic properties

Medications with moderate
anticholinergic properties

Medications with high
anticholinergic properties

Period

APC (95% CI)

2004 – 2015

3.4^ (2.7 – 4.1)

2004 – 2015

6.8^ (5.8 – 7.9)

2004 – 2015

0.0 (-1.5 – 1.5)

2004 – 2011

11.3^ (6.7 – 16.0)

Opioids

2011– 2015

-4.4 (-13.5 – 5.7)

^ Indicates Annual Percent Change (APC) is significantly different from zero at the alpha = 0.05
level
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CHAPTER 7
MANUSCRIPT 2: The Effect of Anticholinergic Use on Cognition and Brain Volume of
Older Adults. Results from the Personality and Total Health (PATH) Through Life Study.
ABSTRACT
Multiple comorbidities are common in older adults, resulting in polypharmacy that often
include medications with anticholinergic properties in this population. These medications have
multiple side effects, which are more pronounced in the older population. This study examined
the association between the use of medications with anticholinergic properties and changes in
cognitive function and brain volume of older adults. The study population consisted of 2222
individuals aged 65-69 years at baseline from the PATH Through Life Study in Australia.
Medication data were obtained from the Pharmaceutical Benefits Scheme (PBS). Cognitive
measures were obtained from neuropsychological battery assessment, while magnetic resonance
imaging (MRI) was used to obtain volumetric brain measures. Exposure to cumulative
anticholinergic use was quantified to Total Standardized Daily Dose (TSDD). The association
between change in cognitive measures between baseline and 4-year follow-up, and cumulative
use of anticholinergic was assessed through generalized linear models. Cumulative use of
anticholinergic resulting in the highest TSDD (>1095) was significantly associated with poorer
performance in Trail Making Test Part B, indicating impairment in executive function.
Anticholinergic use was not associated with changes in brain volume. This study supports
growing evidence that commonly prescribed medications with anticholinergic properties can
72

adversely affect cognitive function in older adults, impacting their aging trajectories and quality
of life.
INTRODUCTION
Multiple comorbidities are common among older adults. Studies show that the prevalence
of comorbidities increases with age.(343, 344) Almost 62% of adults aged 65 years and above
report having several chronic conditions.(14) These conditions are inevitably managed with
pharmaceutical agents, resulting in 90% of older adults using at least one prescribed medication,
many of which contain anticholinergic agents.(1) A significant number of both institutionalized
older adults (approximately 40%) as well as community dwelling older adults (50%) are
prescribed at least one medication with anticholinergic properties. (28, 29)
Medications with anticholinergic properties function by inhibiting the transmission of
acetylcholine in the central nervous system through their antagonistic effects on muscarinic
receptors.(287, 345) In older adults, the association between the use of anticholinergics and
central nervous system adverse effects are particularly important. In this population, the benefits
of using medications with strong anticholinergic properties are outweighed by the risks
associated with these medications.(4) Medications with anticholinergic properties result in
adverse effects ranging from peripheral side effects such as dry mouth to more serious central
nervous system side effects such as hallucinations.(250)
The effects of medications with anticholinergic properties can be particularly profound in
older adults due to age related physiological changes in these individuals. These changes include
increased permeability of the blood brain barrier, fewer cholinergic receptors in the brain and
sub-optimal hepatic and renal function.(30) While earlier studies implied that anticholinergic
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induced adverse effects were largely reversible upon discontinuation, more recent studies
challenge this demonstrating that anticholinergics may cause pathophysiological changes
resulting in cognitive impairment that is not as easily reversible as previously suggested.(7, 26,
31) Anticholinergic drugs may increase the risk of falls among older adults, particularly those
with cognitive impairment.(346) Older adults using anticholinergics also have a higher incidence
of Alzheimer’s disease (AD) and dementia. (268, 269)
This study examined the impact of use of medications with anticholinergic properties on
multiple cognitive domains and changes in brain volume among individuals aged 60 years and
above over a period of 4 years. We also examined if the presence of apolipoprotein E (APOE)
epsilon 4 (ε4) genotype modifies these associations.
METHODS
Study Design
The Personality and Total Health (PATH) Through Life Study is an ongoing longitudinal
cohort study that assesses the lifespan course of multiple diseases and wellbeing among
community dwelling Australian adults. To date, the PATH study has followed three cohorts of
participants starting at ages 20 to 24 years, 40 to 44 years and 60 to 64 years for approximately
19 years. The study participants are from three narrow age cohorts with birth years of 1975-79
(the 20+ cohort), 1956-60 (the 40+ cohort) and 1937-41 (the 60+ cohort) respectively.
Participants of all three cohorts were randomly sampled from the electoral rolls of the Australian
Capital Territory (ACT) and Queanbeyan, Australia.
Wave 1 of the PATH study began between the years 2000 and 2002, and the three
cohorts were followed at 4-year intervals, starting with the youngest cohort, with each cohort
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being interviewed successively over a one-year period. Participation rates for follow-up visits
across the cohorts range from 89% to 93%. Three sub-studies derived from subsamples of the
main PATH study were conducted. These studies were the Magnetic Resonance Imaging (MRI)
study, the Health and Memory study and the Cardiovascular study. The PATH study design and
study population were previously described. (324)
Study Population
This study was conducted on the 60+ cohort of the PATH Through Life study. Data of
from the first follow-up wave (Wave 2, year 2005 / 2006, n = 2222) to the second follow-up
wave (Wave 3, year 2009 / 2010, n=1973) were used. Additionally, data from the MRI sub-study
were used for a sub-sample of the study population from Wave 2 (n=374) and Wave 3 (n=325).
Exposure measure
Data on prescription medication use of study participants were obtained from the
Pharmaceutical Benefit Scheme (PBS). Detailed explanation on the PBS and its use in
pharmaco-epidemiology research is explained elsewhere.(325, 326) The use of medications with
anticholinergic properties between Wave 2 and Wave 3 of the PATH Study was determined for
the exposure measure. Medications with anticholinergic properties were identified using the
Anticholinergic Risk Scale (ARS)(289) and the Anticholinergic Drug Scale (ADS)(283). In the
ARS, medications are classified as having limited or no anticholinergic potential (rated 0),
moderate anticholinergic potential (rated 1), strong anticholinergic potential (rated 2) or very
strong anticholinergic potential (rated 3). In the ADS, medications are classified as having
potential anticholinergic potential (rated 1), moderate anticholinergic potential (rated 2) and
marked anticholinergic potential (rated 3). For this study, medications rated 1 on the ADS and 0
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on the ARS were excluded. Medications not on either of the scale but classified as highly
anticholinergic in the American Geriatrics Society 2012 Beers Criteria for potentially
inappropriate medication use in older adults were included.
The exposure measure for medications with anticholinergic properties was the cumulative
total standardized daily dose (TSDD), as used in past studies.(328) To derive the TSSD, the total
dose of medications with anticholinergic properties in each prescription was calculated by
multiplying medication strength with number of tablets. This value was then divided by the
medication specific recommended minimum effective daily dose per day to derive the
standardized daily dose (SDD).(329) For each study participant, SDD for all medications taken
between Wave 2 and Wave 3 was summed to derive the cumulative TSDD. Study participants
were then classified into categories of cumulative total standardized daily dose based on clinical
significance.(328) The list of medications used by participants in this study is presented in Table
8.
Outcome measures
The outcomes of interest in this analysis were change in participants’ cognitive
function and brain volume from Wave 2 to Wave 3 of the PATH study. Cognitive function was
assessed using multiple neuropsychology tests targeting key cognitive domains. The Mini Mental
State Examination (MMSE) was used to assess global cognition.(347) Short-term memory was
assessed through Immediate Recall and Delayed Recall using the California Verbal Learning
Test.(348) The Wechsler Memory Scale-Digit Span Backward was used to assess working
memory (349) and the Symbol-Digit Modalities Test (350) was used to assess information
processing. Verbal ability was assessed with Spot-the-Word Task (351) while psychomotor

76

speed and information processing was assessed with Simple Reaction Time and Choice Reaction
Time. (352) Trail Making Test, parts A and B was used to assess processing speed (353) and
executive function while Purdue Pegboard Test was used to assess psychomotor speed.(354)
Brain volume measures were obtained from the MRI sub-study formed from a sample
of the larger PATH study. MRI data were obtained using a 1.5 Tesla Gyroscan scanner and T1weighted 3D structural images were done in coronal plane using the Fast Field Echo sequence.
Volumetric measures of brain structures were obtained through volumetric segmentation using
the Freesurfer image analysis suite. Description of the methods used to obtain volumetric
measures of the brain structures were explained in detail elsewhere. (333) Volumetric measures
of interest in this analysis were total brain volume, bilateral hippocampal volume, bilateral
entorhinal cortex volume, bilateral amygdala volume and white matter hypo-intensities.
Covariates
Multiple covariates linked to anticholinergic activity and cognitive function were
included in the analysis. These included demographic factors such as age, sex, and years of
education. Several lifestyle related covariates were also included. Self-reported smoking status
(coded as current smoker, past smoker and never smoked), alcohol consumption (assessed as
drinks per week), and physical activity (categorized as hours of mild, moderate and vigorous
activity) were also included. Covariates representing clinical risk factors were self-reported
stroke, diabetes and family history of dementia, as well as depression assessed with the Patient
Health Questionnaire (PHQ-9).(334) Hypertension status (defined as systolic blood pressure ≥
140mmHg, diastolic blood pressure ≥ 90mmHg or self-reported use of antihypertensives) and
body mass index (BMI) (computed as weight (kg)/ height (m)2) were also included. To assess
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effect modification, the apolipoprotein E (APOE) epsilon 4 (ε4) genotype was added as a
covariate of interest in this analysis. Genotyping for APOE variants in the PATH study
population has been described elsewhere.(335)
Statistical analysis
Data analysis was completed in SAS (v.9.4, SAS Institute Inc., Cary, North Carolina).
Demographic and health related characteristics for the PATH study population and the MRI substudy population at Wave 2 were examined with bivariate analysis using t-tests and Fisher’s
exact test. Generalized Linear Models (GLM) were used to assess the association between
medications with anticholinergic properties, and change in cognitive function and brain volume,
and the effect modification of this association by APOE-ε4 allele. Three statistical models were
used to assess these associations. Model 1 is an unadjusted model, while Model 2 adjusted for
age, sex, and years of education. Additional to demographic factors in Model 2, Model 3
adjusted for lifestyle factors (smoking, alcohol consumption and physical activity), clinical
factors (stroke, diabetes, depression, family history of dementia and BMI), and APOE-ε4 allele.
To minimize Type 1 error due to multiple comparisons, statistical significance was maintained at
0.01.
RESULTS
Population characteristics
Table 9 describes the characteristics of this study population at baseline based on their
exposure to medications with anticholinergic properties. Of the 2222 individuals, 413 were
prescribed at least one medication with anticholinergic properties between baseline and followup. Participants on anticholinergics were more likely to be female compared to those not on
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anticholinergics (62.7% compared to 45.1%). Individuals not on anticholinergics had a lower
BMI (26.6 compared to 27.7) and spent more time doing vigorous physical activity (0.9
hours/week compared to 0.4 hours/week). The percentage of participants with a history of stroke
(5.7% compared to 2.2%), diabetes (13.6% compared to 9.4%) and depression (16.2% compared
to 8.5%) was higher in the group exposed to anticholinergics. Table 10 describes the
characteristics of the MRI sub-study population based on their exposure to medications with
anticholinergic properties. In the sub-study population, individuals on anticholinergics were
more likely to be female compared to those not on anticholinergics (58.9% compared to 42.1%).
The percentage of individuals with depression was also higher in the group exposed to
anticholinergics (21.4% compared to 6.6%).
Association between medications with anticholinergic properties and cognitive function
Table 11 presents the mean change in the cognitive tests from baseline to follow-up
according to the different levels of exposure to anticholinergics. There was generally a decline in
the cognitive function in the study population from baseline to follow-up. This decline was seen
across the comparison groups. Table 12 shows the results from the assessment of the association
between use of medications with anticholinergics and cognitive function from Generalized
Linear Models. Compared to those not on medications with anticholinergic properties, those on
the highest category of TSDD (>1095) had significantly poorer performance in the Trail Making
Test Part B (executive function) (Model 1: β=5.77, Model 2: β=5.33, Model 3: β=8.32, p<0.01).
This association is seen in all three models.
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Association between medications with anticholinergic properties and brain volume
Table 13 presents the mean change in volume of sections of the brain from baseline to
follow-up according to the different levels of exposure to anticholinergics. There was a decline
in volumetric measures in all sections of the brain measured in the study across the exposure
groups. There was also a general increase in white matter hypointensities across the exposure
groups. Medications with anticholinergic properties did not significantly affect changes in brain
volume in the study population. Table 14 shows the results from the assessment of the
association between use of medications with anticholinergics and brain volume from Generalized
Linear Models.
Role of APOE ε-4 allele on the effect of medications with anticholinergic properties on
cognitive function and brain volume
Table 15 presents the effect modification of the association between use of medications
with anticholinergic properties (ACh) and cognitive function by presence of one APOE ε-4 allele
(APOE ε-4 +/-) and presence of both alleles (APOE ε-4 +/+). The interaction term (APOE ε-4
+/-)*ACh was not significantly associated with changes in cognitive function. However, we
found that that the interaction term (APOE ε-4 +/+)*Ach was significantly associated with
decline in Trail Making Test Part B performance in individuals with TSDD of anticholinergics
between 366 to 1095 (β=78.82, p<0.01).
Table 16 presents the effect modification of the association between use of
medications with anticholinergic properties (ACh) and brain volume by presence of at least one
APOE ε-4 allele. Due to the small number of individuals in this sub-study with two APOE ε-4
alleles, effect modification is assessed based on the presence of at least one APOE ε-4 allele. The
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interaction with APOE ε-4 allele and medications with anticholinergic was not significantly
associated with any change in brain volume measures.
DISCUSSION
In this study, we observed significant effects of medications with anticholinergic
properties on the change in cognitive function within the 4 years from baseline to follow-up. We
found that compared to those not using medications with anticholinergic properties, those with a
total standardized daily dose of anticholinergics of 1095 and above during the study period
experienced significant decline in their Trail Making part B test scores, reflecting decline in
executive function. This association remained significant even after adjusting for multiple
covariates. However, we did not find anticholinergic use to be significantly associated with
decline in brain volume. This finding is consistent with previous studies that found
anticholinergics to affect executive function in both older adults (355) as well as among middle
aged adults.(356)
In the United States, 6.8 million ambulatory care visits due to dementia are made
annually, of which 43% of the patients are actively on at least one medication with
anticholinergic properties.(264) This is alarming as multiple studies show that medications with
anticholinergic properties play a role in adversely affecting cognitive function in the elderly. This
association exists in both community dwelling older adults as well as those in residential
care.(265-267) Past studies demonstrate that anticholinergic use increases the risk of
dementia.(269) In a study investigating the effect of anticholinergic use in an older population in
France, the risk of dementia and Alzheimer’s disease was elevated among those with a history of
chronic use of these medications.(357) Chronic use of anticholinergics are also linked to
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Alzheimer’s disease pathology (272) and accelerated decline in cognitive function.(271) In AD
patients, the cholinergic system is particularly affected by the disease. Autopsy brain
investigations of individuals with AD show compromised ACh receptor binding activity and
reduced ACh.(273, 274) AD patients also have fewer cholinergic cells in their forebrain, pointing
to cholinergic loss in the disease.(275)
Our study has several strengths. The PATH Through Life study is a large longitudinal
cohort study which measured cognitive function through a neuropsychology battery assessment
approach, allowing us the unique opportunity to study changes in multiple cognitive domains
over time. Through the MRI sub-study, we were also able to assess volumetric changes in a
sample of this population, allowing us to study effects of these medications on symptoms as well
as pathological changes in the brain. The PATH Through Life study collects data on multiple
covariates, which allowed us to include key covariates in our analysis and further investigate the
role of APOE ε-4 genotype as an effect modifier. Most importantly, through the PBS medication
data, we were able to objectively quantify medication use instead relying on self-reported
medication use, which can be affected by recall bias.
There are some limitations in this study. The PBS database captures information of
medications that are prescribed and filled. It does not provide information on medication
consumption and adherence. Further, it does not capture information of medications purchased
over the counter, many of which can have anticholinergic properties. We took a conservative
approach in determining exposure to medications with anticholinergic properties. Individuals
with no prescription information during the exposure window were classified as not exposed to
anticholinergics. These limitations may have resulted in under-represented exposed individuals
in this study and resulted in underestimation of the measure of effect. The time period between
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the baseline and follow-up visit is short, particularly given that cognitive impairment is often
insidious with onset occurring much earlier before symptoms are apparent. The MRI sub-study
sample is much smaller than the larger PATH Through Life study and is likely underpowered to
detect any associations between medications with anticholinergic properties and brain volume
during a short follow-up period.
This study provides key findings to support the need for further research. Studies with
longer follow-up period will allow us to see the impact of longer cumulative dose of these
medications on cognitive function. A longer follow-up period will also allow us to detect
changes in brain volume in the smaller MRI sub-study population. Future analysis should focus
of the effect of the different classes of anticholinergics to investigate if cumulative use of
anticholinergics from different medication classes produce significantly different effects on the
cognitive and volumetric outcomes we have examined in our study. Due to the importance of the
frontal lobe in the cholinergic system, it would be informative to study volumetric changes in the
frontal lobe of the brain when investigating the effects of cumulative anticholinergic use.
CONCLUSION
This study showed that a high cumulative exposure to medications with
anticholinergic properties had a significant negative effect on executive function in older adults.
Although multiple guidelines have cautioned the use of medications with anticholinergic
properties in older adults, their use in this population is unavoidable due to the multiple
comorbidities, that are managed with these medications. However, prescribers should be aware
of the adverse effects of these medications and seek alternative treatment options when available.
In the event the use of medications with anticholinergic properties is mandatory in older adults,
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prescribers must strive to treat older patients with the lowest effective dose of these medications.
As multiple over the counter medications have anticholinergic properties, it is vital to create
awareness among older adults about the potential modifiable risks of these medications. Future
studies on the impact of the different classes of medications with anticholinergic properties in
older adults will aid in the understanding of the mechanisms of these medications on cognition
and structural changes in the brain in this vulnerable population.
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Table 8: List of medications used by study participants (minimum effective dose)(329)
Antiparkinson agents

Antihistamines
•

Cyproheptadine (4 mg)

•

Benztropine (0.5 mg)

•

Cetirizine (5mg)

•

Trihexyphenidyl (6 mg)

•

Loratadine (10mg)

•

Amantadine (100mg)

•

Levodopa (100mg)

Antidepressants
•

Amitriptyline (10 mg)

•

Carbidopa (25mg)

•

Clomipramine (25 mg)

•

Pramipexole (0.125mg)

•

Doxepin (10 mg)

•

Entacapone (200mg)

•

Imipramine (10 mg)

•

Nortriptyline (10 mg)

•

Chlorpromazine (10 mg)

•

Paroxetine (10 mg)

•

Olanzapine (2.5 mg)

•

Mirtazepine (7.5mg)

•

Quetiapine (50mg)

•

Haloperidol (0.25mg)

•

Risperidone (0.25)

Antipsychotics

Antivertigo/antiemetic
•

Prochlorperazine (15 mg)

•

Promethazine (50 mg)

•

Metoclopramide (10mg)

Bladder antimuscarinics
•

Antacids and antihistamines
•

Ranitidine (150mg)

Gastrointestinal antispasmodics
•

Propantheline (22.5 mg)

•

Loperamide (4mg)

Oxybutynin
o

Patch (3.9 mg)

o

Oral (5 mg)

Skeletal muscle relaxants
•

Baclofen (5mg)

Anticonvulsant
•
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Carbamazepine (400mg)

Table 9: Baseline characteristics of study participants according to anticholinergic use:
PATH Through Life Study, Wave 2, 2005 - 2006
Variable

Not using

Using

anticholinergics

anticholinergics

(N=1809)

(N=413)

66.6 (1.5)

66.6 (1.5)

Male

993 (54.9)

154 (37.3)

Female

816 (45.1)

259 (62.7)

White

1738 (96.1)

395 (95.9)

Asian

40 (2.2)

12 (2.9)

Other

30 (1.7)

5 (1.2)

14.0 (2.7)

13.4 (2.6)

1346 (74.4)

296 (71.7)

Unmarried-living with partner

67 (3.7)

9 (2.2)

Separated

30 (1.7)

15 (3.6)

Divorced

175 (9.7)

45 (10.9)

Widowed

148 (8.2)

40 (9.7)

Never married

42 (2.3)

8 (1.9)

184 (10.2)

13 (3.1)

2 (0.1)

0 (0)

327 (18.1)

55 (13.3)

3 (0.2)

0 (0)

1292 (71.5)

345 (83.5)

Never smoked

972 (53.8)

204 (49.5)

Past smoker

662 (36.6)

167 (40.5)

Current smoker

174 (9.6)

41 (10.0)

Age (years), mean (std)
Gender, n (%)***

Race, n (%)

Education (years), mean (std)***
Marital Status, n (%)
Married

Employment Status, n (%)***
Employed full-time
Employed part-time, looking for
full-time employment
Employed part-time
Unemployed, looking for work
Not in the labor force
LIFESTYLE FACTORS
Smoking Status, n (%)
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7.1 (8.7)

5.7 (7.5)

7.8 (8.6)

8.2 (10.5)

Mild activity

2.8 (4.5)

2.7 (4.5)

Moderate activity

0.9 (0.4)

0.4 (1.2)

Yes

39 (2.2)

23 (5.7)

No

1731 (97.8)

379 (94.3)

Yes

163 (9.4)

55 (13.6)

No

1576 (90.6)

349 (86.4)

Yes

606 (34.1)

128 (31.4)

No

1173 (65.9)

280 (68.6)

26.6 (4.6)

27.7 (5.7)

1628 (91.5)

337 (83.8)

Subsyndromal Depression

71 (4.0)

37 (9.2)

Minor Depression

51 (2.9)

16 (4.0)

Major Depression

30 (1.7)

12 (3.0)

Yes

282 (21.5)

58 (19.6)

No

1031 (78.5)

238 (80.4)

ε4-/ε4-

1231 (72.2)

301 (75.8)

ε4+/ε4-

445 (26.1)

86 (21.7)

ε4+/ε4+

28 (1.6)

10 (2.5)

Alcohol consumption (drinks per week),
mean (std)**
Physical activity (hours per week), mean
(std)

Vigorous activity***
History of Stroke, n (%)***

History of Diabetes, n (%)**

History of Hypertension, n (%)

BMI, mean (std)***
Depression, n (%)***
No Depression

Family History of Dementia, n (%)

Apolipoprotein ε4 allele, n (%)

*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance
at P<0.001

87

Table 10: Baseline characteristics of study participants according to anticholinergic use
(MRI sub-study): PATH Through Life Study, Wave 2, 2005 - 2006
Variable

Not using

Using

anticholinergics

anticholinergics

(N=318)

(N=56)

66.7 (1.4)

66.4 (1.4)

Male

158 (57.9)

23 (41.1)

Female

115 (42.1)

33 (58.9)

White

307 (96.5)

55 (98.2)

Asian

7 (2.2)

1 (1.8)

Other

4 (1.3)

0 (0)

14.2 (2.9)

13.4 (2.8)

205 (75.1)

40 (71.4)

Unmarried-living with partner

10 (3.7)

1 (1.8)

Separated

6 (2.2)

4 (7.1)

Divorced

25 (9.2)

3 (5.4)

Widowed

21 (7.7)

7 (12.5)

Never married

6 (2.2)

1 (1.8)

22 (8.1)

1 (1.8)

0 (0)

0 (0)

50 (18.3)

9 (16.1)

1 (0.4)

0 (0)

200 (73.3)

46 (82.1)

Never smoked

172 (54.1)

26 (46.4)

Past smoker

121 (38.1)

23 (41.1)

25 (7.9)

7 (12.5)

Age (years), mean (std)
Gender, n (%)*

Race, n (%)

Education (years), mean (std)
Marital Status, n (%)
Married

Employment Status, n (%)
Employed full-time
Employed part-time, looking for fulltime employment
Employed part-time
Unemployed, looking for work
Not in the labor force
LIFESTYLE FACTORS
Smoking Status, n (%)

Current smoker
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Alcohol consumption (drinks per week), mean

6.8 (7.9)

6.1 (8.5)

Mild activity

7.0 (7.3)

8.7 (9.6)

Moderate activity

3.0 (4.6)

3.3 (3.8)

Vigorous activity

1.3 (4.3)

0.4 (1.0)

Yes

2 (0.7)

0 (0)

No

268 (99.3)

55 (100.0)

Yes

21 (8.0)

8 (14.3)

No

241 (92.0)

48 (85.7)

Yes

94 (35.1)

15 (26.8)

No

174 (64.9)

41 (73.2)

26.4 (4.5)

26.8 (5.4)

254 (93.4)

44 (78.6)

Subsyndromal Depression

7 (2.6)

8 (14.3)

Minor Depression

9 (3.3)

1 (1.8)

Major Depression

2 (0.7)

3 (5.4)

Yes

52 (24.0)

9 (20.5)

No

165 (76.0)

35 (79.5)

ε4-/ε4-

216 (73.0)

37 (66.1)

ε4+/ε4-

75 (25.3)

19 (33.9)

ε4+/ε4+

5 (1.7)

0 (0)

(std)
Physical activity (hours per week), mean (std)

History of Stroke, n (%)

History of Diabetes, n (%)

History of Hypertension, n (%)

BMI, mean (std)
Depression, n (%)***
No Depression

Family History of Dementia, n (%)

Apolipoprotein ε4 allele, n (%)

*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance
at P<0.001
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Table 11: Association between use of anticholinergic medications (categorized according to clinical significance) and cognitive
function (mean and SD)
MMSE1
No use
Baseline
Followup
Change

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail A10

Trail B11

29.2 (1.3)
29.0 (1.3)

6.9 (2.2)
6.6 (2.2)

6.1 (2.4)
5.8 (2.4)

5.2 (2.2)
5.0 (2.2)

52.9 (5.4)
52.9 (5.3)

49.5 (9.4)
47.2 (9.7)

276.0 (72.1)
283.7 (68.7)

328.4 (51.6)
345.5 (57.5)

13.5 (2.1)
12.2 (2.1)

12.7 (2.0)
11.6 (2.0)

10.4 (1.8)
9.4 (1.9)

35.0 (12.5)
37.5 (14.4)

81.4 (33.7)
88.4 (37.8)

-0.2
(0.02)***

-0.3
(0.03)***

-0.3
(0.04)***

-0.2
(0.03)***

0 (0.1)***

-2.3
(0.1)***

7.7 (1.0)***

17.1
(0.8)***

-1.3
(0.03)***

-1.1
(0.03)***

-1.0
(0.03)***

2.5
(0.2)***

7.0
(0.5)***

TSDD
1-90
Baseline
Followup
Change

29.3 (1.2)
29.0 (1.4)

7.3 (2.3)
6.9 (2.4)

6.4 (2.3)
6.2 (2.4)

4.9 (2.1)
4.7 (2.2)

52.0 (5.0)
51.8 (5.3)

49.5 (9.5)
47.6 (9.1)

290.0 (93.7)
286.1 (61.2)

338.6 (65.5)
346.9 (49.6)

13.5 (2.1)
12.2 (2.2)

12.6 (1.9)
11.5 (2.0)

10.4 (1.8)
9.3 (1.9)

34.5 (9.4)
36.8 (10.6)

78.9 (31.5)
86.0 (31.3)

-0.3
(0.1)***

-0.4
(0.1)**

-0.2 (0.1)

-0.2 (0.1)*

-0.2 (0.3)

-2.1
(0.5)***

-3.9 (4.2)

8.3 (3.1)**

-1.3
(0.1)***

-1.1
(0.1)***

-1.1
(0.1)***

2.3
(0.5)***

7.1
(1.7)***

TSDD
91-365
Baseline
Followup
Change

28.9 (1.3)
28.7 (1.8)

6.7 (2.5)
6.0 (2.1)

5.5 (2.7)
5.3 (2.3)

4.8 (2.1)
4.6 (2.1)

51.4 (5.4)
51.3 (5.5)

49.5 (9.4)
46.0 (9.8)

270.2 (56.7)
282.5 (55.1)

329.1 (45.8)
345.6 (43.7)

13.9 (1.9)
12.2 (2.0)

12.9 (1.9)
12.3 (1.5)

10.7 (1.9)
9.5 (1.7)

32.5 (8.9)
34.9 (9.4)

77.7 (24.5)
92.2 (36.1)

-0.2 (0.2)

-0.7 (0.3)

-0.2 (0.3)

-0.2 (0.2)

-0.1 (0.6)

-3.5
(1.1)**

12.3 (6.2)

16.5 (4.9)**

-1.7
(0.2)***

-0.6
(0.2)**

-1.2
(0.2)***

2.4 (1.0)*

14.5
(3.4)***

29.2 (0.9)
29.2 (1.0)

7.1 (2.1)
6.3 (2.1)

6.1 (2.1)
5.6 (2.1)

5.1 (2.4)
4.7 (2.2)

53.0 (5.3)
52.7 (6.1)

49.7 (6.8)
48.2 (6.6)

272.1 (48.9)
282.2 (44.1)

331.0 (45.9)
340.9 (41.2)

13.7 (2.2)
12.5 (1.9)

12.7 (1.9)
11.6 (2.0)

10.4 (1.9)
9.2 (1.9)

33.4 (8.3)
38.2 (12.4)

81.2 (42.3)
86.9 (30.4)

0 (0.1)

-0.8
(0.2)***

-0.5 (0.2)

-0.4 (0.2)

-0.3 (0.6)

-1.5 (0.7)*

10.1 (4.8)*

9.9 (4.5)*

-1.2
(0.2)***

-1.1
(0.2)***

-1.2
(0.2)***

4.8
(1.1)***

5.7 (3.8)

29.0 (1.3)
28.8 (1.5)

6.5 (2.4)
6.2 (2.4)

5.8 (2.6)
5.4 (2.4)

4.6 (2.1)
4.6 (2.1)

51.3 (5.8)
51.2 (5.9)

306.7 (109.6)
311.5 (94.9)

342.7 (65.3)
363.8 (74.9)

12.9 (2.3)
11.5 (2.4)

12.0 (2.1)
11.0 (2.3)

10.1 (2.0)
8.8 (2.1)

37.6 (14.8)
40.1 (19.0)

-0.2
(0.1)*

-0.3 (0.1)*

-0.4
(0.1)***

0 (0.1)

-0.1 (0.4)

46.6 (9.8)
44.3
(10.1)
-2.3
(0.4)***

4.8 (4.6)

21.1
(3.1)***

-1.4
(0.1)***

-1.0
(0.1)***

-1.3
(0.1)***

2.5 (0.8)**

88.0 (36.0)
100.8
(42.3)
12.8
(1.8)***

TSDD
3661095
Baseline
Followup
Change
TSDD
>1095
Baseline
Followup
Change

Note: 1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test
Part B. Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive values for change indicate cognitive decline. All other measures (MMSE, Immediate
Recall, Delayed Recall, Digit Back, Spot, SDMT, and PPEG) represent number of items completed correctly (negative values for change indicate cognitive decline).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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Table 12: Association between use of anticholinergic medications (categorized according to clinical significance) and cognitive
function (β weights and SE)

TSDD
1-90
Model 1
Model 2
Model 3
TSDD
91-365
Model 1
Model 2
Model 3
TSDD
3661095
Model 1
Model 2
Model 3
TSDD
>1095
Model 1
Model 2
Model 3

MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

-0.13
(0.11)
-0.15
(0.11)
-0.18
(0.13)

-0.01 (0.18)

0.03
(0.18)
0.01
(0.18)
-0.01
(0.21)

-0.10
(0.16)
-0.09
(0.16)
-0.05
(0.18)

-0.22
(0.22)
-0.23
(0.22)
-0.19
(0.25)

0.44
(0.53)
0.30
(0.53)
0.27
(0.60)

-11.53
(6.23)
-11.34
(6.23)
-7.67
(7.28)

-0.03
(0.23)
-0.02
(0.23)
-0.06
(0.26)

-0.33 (0.37)

0.11
(0.38)
0.12
(0.38)
0.16
(0.45)

-0.05
(0.33)
-0.04
(0.33)
0.17
(0.42)

-0.26
(0.53)
-0.27
(0.53)
-0.52
(0.63)

-1.11
(1.08)
-1.13
(1.08)
-0.52
(1.28)

0.11
(0.23)
0.09
(0.23)
-0.23
(0.29)

-0.42 (0.38)

-0.16
(0.37)
-0.17
(0.38)
0.50
(0.48)

-0.26
(0.31)
-0.25
(0.31)
-0.18
(0.41)

-0.43
(0.45)
-0.44
(0.45)
-0.27
(0.55)

0.03
(0.10)
0.03
(0.10)
-0.04
(0.11)

0.04 (0.16)

-0.18
(0.16)
-0.20
(0.16)
-0.20
(0.18)

0.19
(0.14)
0.20
(0.14)
0.28
(0.18)

-0.15
(0.21)
-0.15
(0.12)
-0.37
(0.25)

-0.04 (0.18)
-0.03 (0.21)

-0.32 (0.37)
-0.30 (0.44)

-0.45 (0.38)
-0.25 (0.49)

0.02 (0.16)
-0.10 (0.18)

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail A10

Trail B11

-8.81
(4.03)*
-8.73
(4.05)*
-7.87
(4.77)

0.01
(0.18)
0.02
(0.19)
0.01
(0.21)

-0.03
(0.18)
-0.02
(0.18)
-0.03
(0.21)

-0.12
(0.16)
-0.08
(0.16)
-0.03
(0.18)

-0.15
(1.13)
0.24
(1.14)
0.47
(1.31)

0.12
(2.66)
-0.35
(2.69)
-0.26
(2.88)

4.55
(13.32)
4.77
(13.35)
13.41
(15.17)

-0.65
(8.69)
-0.81
(8.73)
2.56
(10.59)

-0.50
(0.37)
-0.50
(0.37)
-0.49
(0.44)

0.56
(0.37)
0.56
(0.37)
0.60
(0.44)

-0.27
(0.32)
-0.28
(0.32)
-0.09
(0.38)

-0.14
(2.42)
-0.26
(2.41)
-1.29
(2.88)

7.47
(5.10)
7.00
(5.09)
6.35
(6.16)

0.87
(1.04)
0.78
(1.04)
0.01
(1.24)

2.43
(12.86)
2.32
(12.93)
5.76
(15.77)

-7.21
(8.67)
-7.07
(8.74)
-4.09
(10.01)

0.05
(0.34)
0.05
(0.34)
0.14
(0.43)

0.05
(0.33)
0.07
(0.33)
0.09
(0.40)

-0.23
(0.31)
-0.20
(0.30)
-0.15
(0.38)

2.33
(2.31)
2.71
(2.32)
3.04
(2.72)

-1.27
(4.92)
-1.27
(4.91)
-8.62
(5.97)

0.03
(0.46)
-0.07
(0.47)
-0.35
(0.56)

-2.93
(5.40)
-2.64
(5.39)
-5.72
(6.30)

4.03
(3.60)
4.10
(3.64)
2.14
(4.26)

-0.10
(0.16)
-0.10
(0.16)
-0.07
(0.19)

0.17
(0.14)
0.16
(0.15)
0.06
(0.17)

-0.25
(0.14)
-0.22
(0.14)
-0.31
(0.16)

-0.03
(1.04)
0.21
(1.04)
1.14
(1.24)

5.77
(2.27)**
5.33
(2.27)**
8.32
(2.67)**

Note: 1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B. Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use group. All other
measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
Model 1 = unadjusted model
Model 2 = adjusted for age, sex, and education
Model 3 = Model 2 + smoking, alcohol consumption, physical activity, stroke, diabetes, hypertension, BMI, depression & family history of dementia
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Table 13: Association between use of anticholinergic medications (categorized according to clinical significance) and brain
volume in mm3 (mean and SD)
Total Brain

Left
Hippocampus

Right
Hippocampus

Left Entorhinal
Cortex

Right Entorhinal
Cortex

No use
Baseline
1576257.9 (160945.3)
4018.8 (438.2)
4024.3 (424.7)
2094.1 (313.6)
1898.4 (333.1)
Follow-up
1572781.2 (160945.3)
3959.7 (464.1)
3927.8 (456.2)
2046.9 (348.3)
1825.9 (351.5)
Change
-3476.7 (5717.1)
-59.1 (16.0)*** -96.5 (15.7)*** -47.2 (11.8)***
-72.5 (12.2)***
TSDD
1-90
Baseline
1469421.5 (153883.6)
3930.7 (325.4)
3881.1 (417.4)
2054.1 (196.0)
1821.7 (306.9)
Follow-up
1465944.8 (153883.6)
3848.7 (384.1)
3810.3 (422.6)
1916.7 (334.3)
1766.5 (314.0)
Change
-3476.7 (21762.4)
-82.0 (50.4)
-70.8 (59.4)
-137.4 (38.8)***
-55.2 (43.9)
TSDD
91-365
Baseline
1672506.0 (56384.3)
4111.0 (461.5)
4050.9 (458.4)
2339.9 (310.6)
2000.5 (448.2)
Follow-up
1669029.3 (56384.4)
4021.5 (501.0)
3814.2 (411.4)
2277.3 (465.4)
1893.0 (563.5)
Change
-3476.7 (14558.4)
-89.5 (124.4)
-62.6 (102.2)
-107.5 (131.5)
-236.7 (112.5)*
TSDD
366-1095
Baseline
1704038.8 (327991.7)
3857.8 (494.9)
3720.0 (224.5)
2327.8 (257.7)
2144.3 (380.3)
Follow-up
1700562.1 (327991.8)
3800.5 (349.4)
3679.5 (294.3)
2165.1 (263.6)
2001.2 (543.6)
Change
-3476.7 (119765.6)
-57.3 (156.4)
-40.5 (95.6)
-162.7 (95.2)
-143.1 (171.3)
TSDD
>1095
Baseline
1545428.6 (201519.0)
4016.3 (426.0)
3938.0 (455.0)
2050.6 (313.3)
1872.4 (331.0)
Follow-up
1541951.9 (201519.0)
3912.9 (502.9)
3851.1 (520.6)
1973.6 (357.0)
1753.3 (319.4)
Change
-3476.7 (24086.1)
-103.4 (55.7)
-77 (40.1)
-119.1 (38.9)
-86.9 (58.4)**
Note: measures represent brain volume in mm3. Negative values for change indicate decline in volume.
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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Left Amygdala

Right
Amygdala

White Matter
Hyperintensities

1336.2 (212.9)
1300.0 (202.7)
-36.2 (7.4)***

1450.0 (238.9)
1437.9 (208.3)
-12.1 (7.961)

3458.0 (3430.8)
4271.1 (4009.9)
813.1 (132.6)***

1194.5 (156.4)
1203.0 (151.1)
8.5 (21.7)

1318.0 (200.1)
1316.6 (180.2)
-1.4 (26.9)

2923.5 (2476.9)
3792.6 (2719.0)
869.1 (367.8)*

1341.9 (95.2)
1293.7 (114.5)
-48.2 (27.2)

1409.2 (146.2)
1455.2 (156.1)
46.0 (39.0)

3021.9 (2182.8)
3931.1 (2533.8)
909.2 (610.6)

1104.3 (119.2)
1199.7 (149.1)
95.4 (49.3)

1390.6 (125.1)
1346.8 (179.2)
-43.8 (56.4)

2847.1 (1271.6)
3598.9 (1872.5)
751.8 (584.4)

1295.8 (227.5)
1265.3 (259.1)
-30.5 (29.2)

1470.5 (290.2)
1432.9 (269.0)
-37.6 (33.4)

3480.5 (4670.0)
4227.5 (4854.6)
747.0 (569.3)

Table 14: Association between use of anticholinergic medications (categorized according to clinical significance) and brain
volume in mm3 (β weights and SE)
Total Brain

Left
Hippocampus

Right
Hippocampus

Left Entorhinal
Cortex

Right Entorhinal
Cortex

Left Amygdala

Right
Amygdala

TSDD
1-90
Model 1
0.05 (0.03)
-22.93 (63.66)
25.72 (55.50)
-90.29 (53.43)
17.41 (44.48)
44.76 (27.96)
10.66 (31.70)
Model 2
0.05 (0.03)
-52.34 (64.30)
-8.21 (55.24)
-70.61 (54.05)
16.11 (43.64)
45.56 (29.00)
7.00 (32.62)
Model 3
0.04 (0.06)
-34.09 (66.08)
-3.52 (63.84)
-53.63 (59.95)
10.54 (47.97)
23.03 (33.69)
-7.80 (39.74)
TSDD
91-365
Model 1
0.07 (0.05) -30.33 (110.00) -140.20 (105.61) -15.44 (100.67)
-34.87 (90.99)
-11.96 (58.30)
58.00 (64.54)
Model 2
0.07 (0.05) -32.12 (108.73) -138.88 (104.23)
-16.54 (99.44)
-36.95 (90.85)
-9.44 (58.63)
59.94 (64.41)
Model 3
-0.003 (0.13)
92.78 (229.91)
-58.84 (220.51) -189.24 (220.24) -223.51 (173.29) -187.77 (115.37) 7.94 (138.36)
TSDD
366-1095
Model 1
0.05 (0.07)
1.92 (162.70)
55.98 (157.54)
-115.47 (142.84) -70.51 (103.74)
131.59 (76.15)
-31.78 (86.53)
Model 2
0.05 (0.07)
-6.12 (161.30)
46.17 (156.05)
-133.43 (140.77) -75.65 (103.66)
139.55 (75.94)
-26.36 (86.73)
Model 3
0.002 (0.09) -115.61 (163.40) 124.14 (156.29)
-94.07 (155.22)
-61.56 (124.45)
152.79 (81.24)
-23.36 (97.78)
TSDD
>1095
Model 1
0.01 (0.03)
-44.30 (50.39)
9.57 (47.32)
-29.78 (46.84)
-46.60 (35.49)
5.75 (24.02)
-25.61 (29.91)
Model 2
0.01 (0.03)
-58.18 (50.36)
-3.98 (46.65)
-20.39 (46.26)
-48.28 (35.35)
7.31 (23.94)
-26.27 (29.93)
Model 3
0.002 (0.03)
-88.76 (53.99)
-27.10 (47.76)
-40.08 (48.25)
-56.54 (36.99)
2.16 (25.41)
-28.99 (33.74)
Note: : Measures represent brain volume in mm3. Thus, negative β values indicate greater volume loss relative to no anticholinergic use group.
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
Model 1 = unadjusted model
Model 2 = adjusted for age, sex, and education
Model 3 = Model 2 + smoking, alcohol consumption, physical activity, stroke, diabetes, hypertension, BMI, depression & family history of dementia
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White Matter
Hyperintensities

55.97 (301.84)
-3.15 (302.32)
-30.48 (371.00)

96.08 (531.63)
60.38 (527.64)
-635.65 (1241.79)

-61.29 (764.84)
-105.82 (764.37)
-566.62 (884.69)

-66.13 (249.96)
-114.86 (251.35)
-121.72 (261.03)

Table 15: Effect modification of the association between use of anticholinergic medications (categorized according to clinical
significance) and cognitive function (β weights and SE) by apolipoprotein (APOE) ε4 allele

TSDD
1-90
+/+/+
TSDD
91-365
+/+/+
TSDD
3661095
+/+/+
TSDD
>1095
+/+/+

MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail A10

Trail B11

0.14
(0.31)
-0.44
(0.77)

-0.12 (0.50)

-0.03
(0.51)
-1.22
(1.30)

-0.03
(0.41)
-0.89
(1.11)

-0.35
(0.57)
0.48
(1.51)

0.35
(1.35)
1.04
(3.70)

-20.61
(18.09)
-45.76
(43.55)

-9.23
(13.09)
-4.74
(28.35)

0.19
(0.54)
-1.56
(1.24)

-0.07
(0.47)
-0.10
(1.89)

-0.32
(0.42)
-0.19
(1.01)

-1.99
(3.24)
-7.99
(7.95)

0.50
(6.46)
-6.01
(17.69)

0.11
(0.56)
-0.45
(1.28)

-0.01 (0.85)

0.14
(0.85)
-2.54
(2.16)

-0.49
(0.89)
-2.42
(1.88)

0.43
(1.11)
6.07
(2.53)*

-1.55
(2.74)
3.94
(6.14)

-25.71
(30.10)
-101.84
(73.36)

-19.08
(21.84)
-36.11
(47.42)

0.08
(0.81)
0.72
(2.05)

-0.36
(0.80)
-0.92
(1.95)

-0.87
(0.72)
0.79
(1.71)

2.59
(5.35)
-5.72
(13.34)

-4.48
(13.04)
33.96
(29.28)

0.87
(0.49)
1.64
(0.95)

-0.22 (0.82)

-1.49
(0.82)
-3.76
(1.60)*

-0.20
(0.81)
-0.79
(1.38)

-0.13
(0.96)
0.24
(1.86)

1.14
(2.27)
4.75
(4.48)

-21.33
(28.26)
25.43
(54.00)

-17.97
(19.48)
31.56
(34.90)

-0.34
(0.86)
0.64
(1.51)

0.10
(0.74)
-0.60
(1.43)

-0.10
(0.66)
-0.003
(1.26)

-1.89
(4.89)
9.24
(9.83)

12.13
(10.83)
78.82
(21.30)**

0.22
(0.25)
0.92
(0.69)

0.30 (0.37)

-0.10
(0.36)
0.29
(1.14)

-0.25
(0.36)
0.27
(1.01)

0.83
(0.50)
0.99
(1.32)

1.87
(1.09)
-0.54
(3.21)

5.64
(12.49)
13.91
(38.03)

3.32
(8.81)
11.56
(24.49)

0.08
(0.35)
-1.63
(1.10)

0.18
(0.33)
0.09
(1.04)

0.21
(0.31)
0.71
(0.89)

-3.38
(2.29)
-12.03
(6.99)

-8.03
(5.11)
-30.56
(15.77)

-1.74 (1.30)

-1.19 (2.14)

-2.19 (1.60)

0.47 (1.12)

Note: measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use group. All other
measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
+/- = Presence of one APOE-ε4 allele
+/+ = Presence of two APOE-ε4 allele
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Table 16: Effect modification of the association between use of anticholinergic medications (categorized according to clinical
significance) and brain volume in mm3 (β weights and SE) by apolipoprotein (APOE) ε4 allele (+/+ AND +/- vs -/-)
Total Brain

Left
Hippocampus

Right
Hippocampus

Left Entorhinal
Cortex

Right Entorhinal
Cortex

Left Amygdala

Right
Amygdala

White Matter
Hyperintensities

TSDD
1-90
APOE-ε4

-0.02 (0.07)

-151.30 (147.48)

-110.65 (138.96)

-28.06 (127.03)

54.41 (129.01)

52.62 (73.72)

48.27 (89.13)

-392.87 (797.88)

TSDD
91-365
APOE-ε4

0.06 (0.14)

-118.32 (256.71)

-59.38 (244.37)

219.66 (249.16)

252.43 (200.12)

218.53 (128.24)

56.50 (156.38)

795.60 (1362.21)

TSDD
366-1095
APOE-ε4

0.17 (0.16)

263.13 (402.10)

-37.70 (392.20)

-7.13 (317.67)

-54.13 (224.36)

57.81 (179.33)

68.06 (201.17)

1437.10 (1784.29)

TSDD
>1095
APOE-ε4

0.004 (0.09)

31.90 (159.32)

133.12 (153.45)

-29.09 (151.09)

-82.60 (118.79)

35.60 (79.14)

-14.57 (100.37)

268.00 (855.45)

Note: : Measures represent brain volume in mm3. Thus, negative β values indicate greater volume loss relative to no anticholinergic use group.
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
APOE-ε4 = Presence of one or two APOE-ε4 allele
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CHAPTER 8
MANUSCRIPT 3: The Effect of Opioids on Cognition and Brain Volume of Older Adults.
Results from the Personality and Total Health (PATH) Through Life Study.
ABSTRACT
Chronic pain is a common complaint among older adults, and it affects physical and
mental well-being of these individuals. While opioid use for pain management has increased
over the years, pain management in older adults is challenging and the use of opioids in this
population may result in severe adverse effects. The aim of this study was to examine the
association between opioid use, and changes in cognitive function and brain volume of
community dwelling older adults. The study population consisted of 2222 individuals aged 65-69
years at baseline from the PATH Through Life Study in Australia. Medication data were
obtained from the Pharmaceutical Benefits Scheme (PBS). Cognitive measures were obtained
from neuropsychological battery assessment, while magnetic resonance imaging (MRI) was used
to obtain volumetric brain measures. Exposure to opioids was quantified as Total Morphine
Equivalent Dose (MED). The association between change in cognitive and brain volume
measures between baseline and 4-year follow-up, and cumulative use of opioids was assessed
through generalized linear models. Cumulative exposure to opioids exceeding total MED of
2940 was significantly associated with poorer performance in the Mini Mental State Examination
(MMSE), indicating impairment in global cognitive function. Opioid use was not associated with
changes in brain volume in this study. This study supports the need to address the adverse
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outcomes due to opioid use in older adults and encourages efforts to use alternative pain
management strategies in this population. While addressing chronic pain is vital for improving
quality of life, options for management should not adversely affect healthy aging trajectories and
cognitive health in older adults.
INTRODUCTION
Older adults commonly complain about persistent pain. Among older adults in nursing
homes, persistent pain is reported in approximately 80% of the population. Close to 50% of
community dwelling older adults report similar complaints. (11) Chronic pain in older adults is
linked to impaired physical function and psychological distress. (358) Pain management in this
population has its unique challenges due to age related risks of adverse effects as well as the high
prevalence of polypharmacy among older adults.(359)
While it is not recommended as the first choice of chronic pain management in older
adults, opioids are being prescribed more often now and for longer period of use among older
adults. (12-14) At least one prescription of opioid is filled in a year by 18% of adults in the
United States.(360) Among older adults, multiple adverse effects of opioid use have been
reported. These include side effects such as nausea, constipation, urinary retention, sedation and
dizziness.(307, 317, 318) Opioids are also associated with delirium (319) and have been reported
to result in cognitive impairment as well as hallucinations in older adults.(320, 321)
Chronic exposure to opioids can introduce tolerance and more seriously, dependence to
the drugs.(314) Tolerance is a result of a desensitization mechanism and will result in the need
for higher doses to produce the desired effect. This is particularly dangerous in the elderly, due to
dose-response related adverse events. (314) Opioids are also shown to affect cellular biology in
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the brain, which can promote the development and progression of neurodegenerative diseases.
(38)
This study aimed to examine the association between prescription opioid use in older
adults and changes in cognitive function and brain volume over a period of 4 years. We also
examined the effect modification of this association by the apolipoprotein E (APOE) epsilon 4
(ε4) gene.
METHODS
Study Design
The Personality and Total Health (PATH) Through Life Study aimed to assess the course
of diseases over the lifespan of adults living in the community through a longitudinal cohort
study design. Conducted among Australian adults, the PATH study sample consisted of 3
separate cohorts. To date, the PATH study has followed the three cohorts of participants starting
at ages 20 to 24 years, 40 to 44 years and 60 to 64 years for approximately 19 years. Age cohorts
were narrow with birth years 1975-79, 1956-60, and 1937-41 for the 20+ cohort, the 40+ cohort
and the 60+ cohort respectively. Participants were randomly selected from the electoral rolls of
the Australian Capital Territory (ACT) and Queanbeyan, Australia.
Starting between the year 2000 and 2002, the study cohorts were followed at 4-year
intervals. Starting with the 20+ cohort, each cohort was interviewed successively. Participation
rates for follow-up visits across the cohorts ranged from 89% to 93%. Three sub-studies derived
from sub-samples of the main PATH study have been done. These studies are the Magnetic
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Resonance Imaging (MRI) study, the Health and Memory study and the Cardiovascular study.
The PATH study design and study population were previously described. (324)
Study Population
This study focuses on the 60+ cohort of the PATH Through Life study. Baseline data for
this study was obtained from the first follow-up wave of the PATH study (Wave 2, year 2005 /
2006, n = 2222) and 4-year follow-up data were obtained from the second follow-up wave of the
PATH study (Wave 3, year 2009 / 2010, n=1973). Similarly, volumetric brain measures were
obtained from the MRI sub-study of the parent study from Wave 2 (n=374) and Wave 3 (n=325).
Exposure measure
Medication data for this study were obtained from the Pharmaceutical Benefit Scheme
(PBS). The PBS and pharmaco-epidemiology research done using PBS is described
elsewhere.(325, 326) The total morphine equivalent dose (MED) of opioids used between Wave
2 and Wave 3 of the PATH Study was used to quantify the exposure measure in this study.
Medications listed as opioids according to the World Health Organization Anatomical
Therapeutic Chemical classification system was included in this study.(327) Total MED was
derived by first computing the product of the quantity of opioids by their respective strengths.
This product was then multiplied with medication specific morphine conversion factors. (331,
332) The list of opioids used by participants and their respective morphine conversion factors in
this study is presented in Table 17.
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Outcome measures
Outcomes of interest in this study were changes in cognitive function and brain
volume from baseline to 4-year follow-up. Multiple cognitive domains were assessed through a
series of neuropsychological tests. The Mini Mental State Examination (MMSE) was used to
assess global cognition.(347) Short-term memory was assessed through Immediate Recall and
Delayed Recall using the California Verbal Learning Test.(348) The Wechsler Memory ScaleDigit Span Backward was used to assess working memory (349) and the Symbol-Digit
Modalities Test (350) was used to assess information processing. Verbal ability was assessed
with Spot-the-Word Task (351) while psychomotor speed and information processing was
assessed with Simple Reaction Time and Choice Reaction Time. (352) Trail Making Test, parts
A and B were used to assess processing speed (353) and executive function while Purdue
Pegboard Test was used to assess psychomotor speed.(354)
Changes in brain volume were assessed in a sub-sample of the parent PATH study
through the MRI sub-study. MRI data were obtained using a 1.5 Tesla Gyroscan scanner and T1weighted 3D structural images were done in coronal plane using the Fast Field Echo sequence.
Volumetric segmentation using the Freesurfer image analysis suite was used to obtain the
volumetric measures of brain structures. Detailed methods used to obtain the volumetric
measures of brain structures in the MRI sub-study are explained in detail elsewhere. (333) In
this study, the volumetric measures of interest were total brain volume, bilateral hippocampal
volume, bilateral entorhinal cortex volume, bilateral amygdala volume and white matter hypointensities.
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Covariates
Multiple covariates linked to opioids and cognitive function were included in the
analysis. These included demographic factors such as age, sex, and years of education. Selfreported smoking status (coded as current smoker, past smoker and never smoked), alcohol
consumption (assessed as drinks per week), and physical activity (categorized as hours of mild,
moderate and vigorous activity) were also included in the analysis. Clinical risk factors such as
self-reported stroke, diabetes and family history of dementia, as well as depression assessed with
the Patient Health Questionnaire (PHQ-9) were included as covariates in the final model.(334)
Additionally, hypertension status (defined as systolic blood pressure ≥ 140mmHg, diastolic
blood pressure ≥ 90mmHg or self-reported use of antihypertensives) and body mass index (BMI)
(computed as weight (kg)/ height (m)2) were also included. Apolipoprotein E (APOE) epsilon 4
(ε4) genotype was added as a covariate of interest in this analysis and used to assess effect
modification. Genotyping for APOE variants in the PATH study population is described
elsewhere.(335)
Statistical analysis
Data analysis was completed in SAS (v.9.4, SAS Institute Inc., Cary, North Carolina).
Demographic and health related characteristics for the PATH study population and the MRI substudy population at Wave 2 were examined with bivariate analysis using t-tests and Fisher’s
exact test. Generalized Linear Models (GLM) were used to assess the association between
opioids and change in cognitive function and brain volume, and the effect modification of this
association by APOE-ε4 allele. Three statistical models, representing an unadjusted model
(Model 1), a partially adjusted model for demographic variables (Model 2) and a fully adjusted
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model with all covariates (Model 3) were used to assess these associations. To minimize Type 1
error due to multiple comparisons, statistical significance was maintained at 0.01.
RESULTS:
Population characteristics
Table 18 describes the baseline study population characteristics based on opioid
exposure. In this study, 440 individuals (19.8%) were prescribed opioids during the study period.
Individuals on opioids had lower total years of education (13.3 years compared to 14.1 years)
and higher BMI (28.3 compared to 26.4). Compared to those not on opioids, a higher percentage
of individuals who were on opioids were not in the labor force (79.3% compared to 72.3%) and
were past smokers (41.5 % compared to 36.3%) or currently smoking (15.3% compared to
8.3%). The percentage of participants with a history diabetes was higher in the group exposed to
opioids (14.9% compared to 9.0%). The percentage of individuals with depression was also
higher among those exposed to opioids compared to those not exposed to opioids (16.3%
compared to 8.4%).
Table 19 describes the characteristics of the MRI sub-study population based on their
exposure to opioids. In the sub-study population, individuals on opioids had lower total years of
education (13.1 years compared to 14.3 years) and higher BMI (28.2 compared 26.3). The
percentage of individuals who were past smokers (37.1 compared to 33.9) or were currently
smoking (17.7 compared to 5.5) were also higher among those on opioids. This trend was also
seen among those with depression (23.0% compared to 9.2%).
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Association between opioids and cognitive function
Table 20 presents the mean change in the cognitive tests from baseline to follow-up
according to the different levels of exposure to opioids. There was generally a decline in the
cognitive function in the study population from baseline to follow-up. However, the severity of
decline in the Trail Making B test appeared to increase as the total MED of opioid exposure
during the study period increased, from 7.1 in the unexposed group to 13.1 in the group with the
highest opioid exposure (MED >2940).
Table 21 shows the results from the assessment of the association between use of
opioids and cognitive function from Generalized Linear Models. Compared to those not on
opioids, individuals exposed to opioids resulting in total MED of greater than 2940 had
significantly lower scores in the Mini Mental State Examination (Model 1: β=-0.34, Model 2:
β=-0.35, and Model 3: β=-0.39, p<0.01). While exposure at this level appeared to affect
performance in the Purdue Pegboard Test for dominant hand (Model 1: β= -0.49, Model 2: β= 0.49, and Model 3: β= -0.53) the findings were not statistically significant at p<0.01.
Association between opioids and brain volume
Table 22 presents the mean change in volume of sections of the brain and white matter
hypointensities from baseline to follow-up according to the different levels of exposure to
opioids. There was a decline in volumetric measures in all sections of the brain of study
participants measured in the study across the population. There was also a general increase in
white matter hypointensities, with the highest increase seen in those with a cumulative opioid
exposure with total MED exceeding 2940 (764.6mm3 in the unexposed group compared to
1538.5mm3 in the group exposed to opioids with MED > 2940). Table 23 present the association
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between use of opioids and brain volume assessed using Generalized Linear Models. Opioid use
at the highest category of total MED appear to increase white matter hypointensities (Model 1:
β= 773.92, Model 2: β= 738.08), however, this association was not significant at p<0.01.
Role of APOE ε-4 allele on the effect of opioids on cognitive function and brain volume
Table 24 presents the effect modification of the association between opioid use and
cognitive function by presence of one APOE ε-4 allele (APOE ε-4 +/-) and presence of both
alleles (APOE ε-4 +/+). The changes in performance in all the cognitive domains that were
assessed were not significantly associated with the interaction term (APOE ε-4 +/-)*opioid. The
interaction term (APOE ε-4 +/+)*Ach was significantly associated with decline in Immediate
Recall ( β= -5.71, p<0.01) and Delayed Recall (β= -7.38, p<0.001) test scores among individuals
with opioid intake exceeding cumulative total MED of 2940.
Table 25 presents the effect modification of the association between use of opioids
and brain volume by presence of at least one APOE ε-4 allele. Due to limited sample size of the
MRI sub-study, only a few individuals within the sub-study had two APOE ε-4 alleles.
Therefore, effect modification is assessed based on the presence of at least one APOE ε-4 allele.
The interaction with APOE ε-4 allele and opioids was not significantly associated with any
change in brain volume measures.
DISCUSSION
In this study, we observed the significant effects of opioids on the change in cognitive
function within the 4 years from baseline to follow-up. We found that compared to those not
exposed to opioids, individuals with a total MED of above 2940 experienced significant decline
in their MMSE scores, reflecting decline in global cognitive function. This association remained
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significant even after adjusting for multiple covariates. However, we found that exposure to
opioids was not significantly associated with decline in brain volume.
Many older adults experience pain daily, with some reporting significant pain that
interferes with their normal functioning.(293) The prevalence of chronic pain increases with
age.(294-296) This age-related increase is not limited to just joint pain, as commonly expected in
the elderly population.(297) The most common causes of chronic pain in this population is
arthritis and neuralgias.(35) Compared to those in long-term care facilities, community dwelling
older adults are more likely to complain about chronic pain.(298, 299) Chronic pain in older
adults should not be ignored as it results in poor daily functioning, affected mood and withdrawal
from recreational activities, all of which can adversely affect healthy aging.(300, 301) With the
increase in the prevalence of chronic pain in the elderly, the management of pain in older adults
through opioids has increased.(304-306)
Pharmacological intervention for pain in the elderly must be approached with caution.
The geriatric population is considered a challenging population to treat for pain because of
multiple issues related to existing comorbidities, age related increase in the risk of cognitive
impairment and inherent polypharmacy. (309) Opioid use in the elderly is linked to multiple
adverse effects. Opioids are associated with episodes of delirium in older adults, which a risk
factor for cognitive impairment (319) Opioids may also cause hallucinations in the elderly. (320,
321) A common side effect of opioids is sedation which can cause psychomotor
impairment.(322) Evidence also indicates that opioids influence learning and memory. (323)
Opioids block pain through the disruption of normal neurotransmitter activity in the brain, which
could lead to these impairments.
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This study has several strengths. The PATH Through Life study used a longitudinal
cohort study design on a large sample of population dwelling individuals. The study measured
cognitive function using comprehensive neuropsychology assessments and provides us the
opportunity to study longitudinal changes in multiple cognitive domains over time. The MRI
sub-study provided important neuroimaging data vital to assess pathological changes in brain
structures. This allowed us to explore the effects of opioids on symptoms of cognitive
impairment as well as physical changes in the brain. The PATH Through Life study also
collected data on multiple covariates, which allowed us to include important covariates in our
analysis and further investigate the role of APOE ε-4 genotype as an effect modifier. The PATH
study captured medication use of participants through the PBS medication database. This
allowed us to objectively quantify opioid medication use and avoid recall bias by relying solely
on self-reported opioid use.
This study also has some limitations. The PBS database captured information of
medications that are prescribed and filled. It did not provide information of medication
consumption and adherence. We are also unable to obtain information on opioid abuse beyond
prescribed opioids. We took a conservative approach in determining exposure to opioids.
Individuals with no prescription information during the exposure window were classified as not
exposed to opioids. These limitations may have resulted in misclassification of exposed
individuals in this study and resulted in underestimation of the measure of effect. The time
period between the baseline and follow-up visit is short, particularly given that cognitive
impairment is often insidious with onset occurring far early before symptoms are apparent. The
MRI sub-study sample is much smaller than the larger PATH Through Life study and is likely
underpowered to detect any associations in a short follow-up period.
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Our study supports the need to further investigate the role of opioid use on cognitive
function in older adults. Future studies with longer follow-up period will allow us to investigate
the impact of chronic opioid use. Within the MRI sub-study, longer follow-up period may allow
us to detect actual changes in brain volume more effectively. Future studies should also measure
days of opioid use, which we were unable to obtain as a secondary measure of opioid exposure.
This method will allow us to assess chronic exposure to opioids more effectively.
CONCLUSION
This study showed that exposure to opioids exceeding a total MED of 2940 over a period
of 4 years significantly affects global cognition in older adults. Exposure at this level can also
potentially affect psychomotor speed. The opioid epidemic is an important public health concern
and this concern should not be disregarded in the older population. Physicians providing care to
older adults must be aware of the adverse effects of this option of pain management. Healthcare
providers must strive to use alternative options and methods of pain management when feasible,
especially in the older population. It is essential for opioid awareness programs to expand to
reach older adults as well, as awareness on the adverse effects of opioids on healthy aging can
educate older adults to advocate for themselves when it comes to pain management.
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Table 17: List of medications used by study participants (morphine conversion factor)(331,
332)
Natural opium alkaloids
•

Codeine phosphate hemihydrate (0.15)

•

Morphine sulfate pentahydrate (1.00)

•

Morphine hydrochloride trihydrate (1.00)

•

Oxycodone hydrochloride (1.50)

•

Hydromorphone hydrochloride (4.00)

•

Oxycodone hydrochloride + naloxone hydrochloride (1.50)

Diphenylpropylamine derivatives
•

Methadone hydrochloride (3.00)

Phenylpiperidine derivatives
•

Fentanyl (7.20)

Oripavine derivatives
•

Buprenorphine (12.60)

Opioids in combination with non-opioid analgesics
•

Paracetamol + codeine phosphate hemihydrate (0.15)

Other opioids
•

Tramadol hydrochloride (0.10)

•

Tapentadol (0.40)
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Table 18: Baseline characteristics of study participants according to opioid use: PATH
Through Life Study, Wave 2, 2005 - 2006
Variable

Not using opioids

Using opioids

(N=1782)

(N=440)

66.6 (1.5)

66.6 (1.5)

Male

935 (52.5)

212 (48.2)

Female

847 (47.5)

228 (51.8)

White

1703 (95.6)

430 (97.9)

Asian

47 (2.6)

5 (1.1)

Other

31 (1.8)

4 (0.9)

14.1 (2.7)

13.3 (2.6)

1328 (74.6)

314 (71.4)

Unmarried-living with partner

64 (3.6)

12 (2.7)

Separated

36 (2.0)

9 (2.0)

Divorced

168 (9.4)

52 (11.8)

Widowed

142 (8.0)

46 (10.5)

Never married

43 (2.4)

7 (1.6)

180 (10.1)

17 (3.9)

1 (0.1)

1 (0.2)

310 (17.4)

72 (16.4)

2 (0.1)

1 (0.2)

1288 (72.3)

349 (79.3)

Never smoked

986 (55.4)

190 (43.3)

Past smoker

647 (36.3)

182 (41.5)

Current smoker

148 (8.3)

67 (15.3)

Age (years), mean (std)
Gender, n (%)

Race, n (%)

Education (years), mean (std)***
Marital Status, n (%)
Married

Employment Status, n (%)**
Employed full-time
Employed part-time, looking for fulltime employment
Employed part-time
Unemployed, looking for work
Not in the labor force
LIFESTYLE FACTORS
Smoking Status, n (%)***
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Alcohol consumption (drinks per week), mean

6.8 (8.4)

7.0 (8.8)

Mild activity

7.8 (8.9)

8.2 (9.4)

Moderate activity

2.8 (4.7)

2.6 (4.8)

Vigorous activity

0.8 (2.5)

0.6 (2.1)

Yes

44 (2.5)

18 (4.2)

No

1698 (97.5)

412 (95.8)

Yes

155 (9.0)

63 (14.9)

No

1564 (91.0)

361 (85.1)

Yes

607 (34.7)

127 (29.1)

No

1144 (65.3)

309 (70.9)

BMI, mean (std)***

26.4 (4.6)

28.3 (5.6)

1605 (91.6)

360 (83.7)

Subsyndromal Depression

66 (3.8)

42 (9.8)

Minor Depression

50 (2.9)

17 (4.0)

Major Depression

31 (1.8)

11 (2.6)

Yes

278 (21.6)

62 (19.3)

No

1010 (78.4)

259 (80.7)

ε4-/ε4-

1222 (72.7)

310 (74.0)

ε4+/ε4-

429 (25.5)

102 (24.3)

ε4+/ε4+

31 (1.8)

7 (1.7)

(std)
Physical activity (hours per week), mean (std)

History of Stroke, n (%)

History of Diabetes, n (%)**

History of Hypertension, n (%)*

Depression, n (%)***
No Depression

Family History of Dementia, n (%)

Apolipoprotein ε4 allele, n (%)

*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance
at P<0.001

110

Table 19: Baseline characteristics of study participants according to opioid use (MRI substudy): PATH Through Life Study, Wave 2, 2005 - 2006
Variable

Not using opioids

Using opioids

(N=311)

(N=63)

66.6 (1.4)

66.5 (1.4)

Male

176 (56.6)

33 (52.4)

Female

135 (43.4)

30 (47.6)

White

293 (94.5)

59 (95.2)

Asian

10 (2.2)

0 (0)

Other

7 (2.3)

3 (4.8)

14.3 (2.8)

13.1 (2.6)

251 (80.7)

47 (74.6)

Unmarried-living with partner

10 (3.2)

0 (0)

Separated

4 (1.3)

1 (1.6)

Divorced

21 (6.8)

6 (9.5)

Widowed

22 (7.1)

8 (12.7)

Never married

3 (1.0)

1 (1.6)

32 (10.3)

3 (4.8)

1 (0.3)

0 (0)

70 (22.5)

8 (12.7)

1 (0.3)

1 (1.6)

207 (66.6)

51 (81.0)

Never smoked

188 (60.6)

28 (45.2)

Past smoker

105 (33.9)

23 (37.1)

17 (5.5)

11 (17.7)

6.9 (8.2)

7.1 (10.7)

Age (years), mean (std)
Gender, n (%)

Race, n (%)

Education (years), mean (std)**
Marital Status, n (%)
Married

Employment Status, n (%)
Employed full-time
Employed part-time, looking for full-time
employment
Employed part-time
Unemployed, looking for work
Not in the labor force
LIFESTYLE FACTORS
Smoking Status, n (%)**

Current smoker
Alcohol consumption (drinks per week), mean (std)
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Physical activity (hours per week), mean (std)
Mild activity

7.7 (7.9)

9.1 (12.0)

Moderate activity

2.8 (3.6)

2.2 (3.6)

Vigorous activity

0.7 (1.8)

0.8 (3.3)

Yes

6 (2.0)

2 (3.3)

No

297 (98.0)

58 (96.7)

Yes

30 (9.9)

8 (13.8)

No

274 (90.1)

50 (86.2)

Yes

112 (36.1)

19 (30.6)

No

198 (63.9)

43 (69.4)

BMI, mean (std)**

26.3 (4.0)

28.2 (4.8)

278 (90.8)

47 (77.0)

Subsyndromal Depression

7 (2.3)

9 (14.8)

Minor Depression

12 (3.9)

3 (4.9)

Major Depression

9 (2.9)

2 (3.3)

Yes

61 (23.0)

5 (20.5)

No

204 (77.0)

43 (89.6)

ε4-/ε4-

213 (71.7)

42 (70.0)

ε4+/ε4-

80 (26.9)

1 (30.0)

ε4+/ε4+

4 (1.3)

0 (0)

History of Stroke, n (%)

History of Diabetes, n (%)

History of Hypertension, n (%)

Depression, n (%)***
No Depression

Family History of Dementia, n (%)

Apolipoprotein ε4 allele, n (%)

*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance
at P<0.001
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Table 20: Association between use of opioids (categorized according to quartiles of total morphine equivalent dose) and
cognitive function (mean and SD)
MMSE1
No use
Baseline
Followup
Change

MED
0.01180.00
Baseline
Followup
Change
MED
180.01387.30
Baseline
Followup
Change
MED
387.312940.00
Baseline
Followup
Change
MED
>2940.00
Baseline
Followup
Change

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

29.2 (1.3)
29.0 (1.3)

7.0 (2.2)
6.6 (2.2)

6.1 (2.4)
5.9 (2.3)

5.2 (2.2)
5.0 (2.2)

52.9 (5.4)
52.9 (5.4)

50.0 (9.4)
47.3 (9.7)

-0.2
(0.02)***

-0.4
(0.03)***

-0.2
(0.04)**
*

-0.2
(0.03)**
*

0 (0.08)

29.2 (1.1)
28.9 (1.3)

6.6 (2.2)
6.2 (2.3)

5.7 (2.4)
5.3 (2.5)

4.9 (2.1)
4.8 (2.2)

-0.3
(0.1)***

-0.4
(0.1)***

-0.4
(0.1)**

28.9 (1.6)
28.9 (1.7)

6.6 (2.3)
6.4 (2.5)

0 (0.1)

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail A10

Trail B11

278.8 (77.4)
284.7 (68.7)

329.8 (54.3)
346.2 (58.1)

13.5 (2.1)
12.2 (2.1)

12.7 (1.9)
11.6 (2.0)

10.4 (1.8)
9.4 (1.9)

34.9 (12.2)
37.3 (14.2)

81.2 (33.7)
88.3 (37.8)

-2.7
(0.1)***

5.9 (1.1)***

16.4
(0.8)***

-1.3
(0.03)***

-1.1
(0.03)***

-1.0
(0.03)***

2.4
(0.2)***

7.1
(0.5)***

51.2 (4.9)
52.2 (4.9)

48.8 (8.6)
46.0 (8.6)

282.9 (64.5)
285.0 (68.2)

332.3 (52.0)
347.4 (59.1)

13.4 (2.0)
12.2 (2.1)

12.6 (1.9)
11.6 (2.0)

10.4 (2.0)
9.4 (2.0)

36.3 (12.8)
37.8 (12.7)

83.3 (31.2)
91.3 (36.1)

-0.1
(0.1)

1.0 (0.2)

-2.8
(0.4)***

2.1 (3.3)

15.1
(2.8)***

-1.2
(0.1)***

-1.0
(0.1)***

-1.0
(0.1)***

1.5 (0.6)*

8.0
(1.7)***

5.8 (2.7)
5.8 (2.6)

5.1 (2.0)
4.9 (2.3)

51.5 (5.4)
51.2 (5.3)

49.5 (10.5)
47.7 (10.5)

277.8 (102.7)
296.8 (108.7)

325.5 (63.5)
350.1 (78.7)

13.1 (2.4)
12.1 (2.1)

12.8 (2.5)
11.4 (2.2)

10.3 (1.9)
9.4 (2.02)

36.5 (17.0)
38.9 (25.7)

83.4 (36.9)
93.8 (39.8)

-0.2 (0.2)

0 (0.2)

-0.2
(0.2)

-0.3 (0.4)

-1.8 (0.8)*

19.0 (8.3)*

24.6
(5.6)***

-1.0
(0.2)***

-1.4
(0.2)***

-0.9
(0.2)***

2.4 (1.7)

10.4
(3.0)**

29.1 (1.2)
28.8 (1.5)

6.9 (2.3)
6.6 (2.4)

6.0 (2.3)
5.7 (2.2)

4.7 (2.0)
4.5 (2.0)

51.8 (5.5)
51.7 (5.8)

47.7 (9.4)
45.7 (9.3)

286.9 (91.1)
296.6 (81.9)

336.3 (51.9)
354.2 (59.8)

13.3 (2.1)
11.8 (2.4)

12.3 (2.2)
11.4 (2.2)

10.1 (2.0)
9.1 (2.0)

36.5 (14.5)
39.7 (16.1)

88.1 (39.4)
95.5 (42.1)

-0.3
(0.1)**

-0.3 (0.1)*

-0.3
(0.1)*

-0.2
(0.1)

-0.1 (0.3)

-2.0
(0.6)***

9.7 (5.2)

17.9
(3.3)***

-1.5
(0.1)***

-0.9
(0.1)***

-1.0
(0.1)***

3.2
(0.9)***

7.4 (2.4)**

29.2 (1.1)
28.8 (1.7)

6.5 (2.2)
6.3 (2.3)

6.0 (2.4)
5.6 (2.3)

4.8 (2.4)
4.5 (2.4)

52.1 (5.6)
52.1 (5.5)

46.8 (9.1)
43.7 (9.8)

281.4 (69.3)
299.1 (68.4)

333.3 (47.9)
353.1 (49.8)

12.8 (2.3)
11.1 (2.4)

11.9 (2.1)
10.7 (2.3)

10.0 (2.0)
8.6 (2.2)

35.0 (9.9)
40.0 (12.4)

82.6 (31.5)
95.7 (35.6)

-0.4
(0.9)***

-0.2 (0.1)

-0.4
(0.1)**

-0.3
(0.1)*

0 (0.3)

-3.1
(0.6)***

17.7 (4.2)***

19.8
(3.0)***

-1.7
(0.1)***

-1.2
(0.1)***

-1.4
(0.1)***

5.0
(0.7)***

13.1
(2.1)***

Note: 1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B. Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive values for change indicate cognitive decline. All other measures (MMSE, Immediate
Recall, Delayed Recall, Digit Back, Spot, SDMT, and PPEG) represent number of items completed correctly (negative values for change indicate cognitive decline).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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Table 21: Association between use of opioids (categorized according to quartiles of total morphine equivalent dose) and
cognitive function (β weights and SE)
MED
0.01-180.00
Model 1
Model 2
Model 3

MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail A10

Trail B11

-0.09
(0.11)
-0.09
(0.11)
-0.08
(0.13)

-0.02 (0.18)

-0.15
(0.18)
-0.17
(0.18)
-0.24
(0.21)

0.06
(0.15)
0.06
(0.15)
0.07
(0.18)

0.38
(0.25)
-0.54
(0.50)
-0.56
(0.50)

-0.55
(0.50)
-0.56
(0.50)
-0.26
(0.60)

-3.91
(6.30)
-3.60
(6.30)
-6.64
(7.33)

-1.26
(3.85)
-1.09
(3.86)
1.51
(4.50)

0.04
(0.18)
0.03
(0.18)
0.05
(0.21)

0.26
(0.16)
0.24
(0.16)
0.15
(0.19)

0.05
(0.15)
0.05
(0.15)
-0.01
(0.17)

-0.93
(1.12)
-0.85
(1.12)
-0.70
(1.33)

0.84
(2.41)
0.84
(2.41)
3.90
(3.03)

0.13
(0.16)
0.13
(0.16)
0.18
(0.19)

0.21 (0.27)

0.24
(0.26)
0.23
(0.26)
0.47
(0.31)

-0.12
(0.24)
-0.11
(0.23)
-0.09
(0.28)

-0.26
(0.34)
0.39
(0.77)
0.37
(0.77)

0.39
(0.77)
0.37
(0.77)
0.41
(0.87)

13.11
(9.14)
13.72
(9.12)
19.17
(10.65)

8.27
(6.38)
8.29
(6.40)
12.60
(7.48)

0.17
(0.25)
0.17
(0.25)
-0.02
(0.30)

-0.17
(0.24)
-0.20
(0.24)
-0.30
(0.29)

0.07
(0.22)
0.06
(0.22)
0.02
(0.26)

-0.06
(1.67)
-0.12
(1.66)
0.35
(1.94)

3.22
(3.68)
2.74
(3.70)
3.65
(4.23)

-0.13
(0.13)
-0.15
(0.13)
-0.17
(0.16)

0.11 (0.20)

-0.07
(0.20)
-0.10
(0.20)
0.002
(0.25)

-0.09
(0.19)
-0.08
(0.19)
0.02
(0.23)

-0.10
(0.25)
0.25
(0.59)
0.15
(0.59)

0.25
(0.59)
0.15
(0.59)
0.30
(0.71)

3.77
(7.09)
4.28
(7.19)
-0.28
(8.81)

1.52
(4.97)
1.83
(5.03)
-2.07
(6.27)

-0.25
(0.20)
-0.26
(0.20)
-0.20
(0.26)

0.17
(0.20)
0.17
(0.20)
-0.004
(0.25)

0.06
(0.17)
0.09
(0.17)
-0.05
(0.21)

0.76
(1.31)
1.11
(1.31)
0.44
(1.49)

0.21
(2.98)
-0.004
(2.98)
-0.33
(3.93)

-0.34
(0.13)**
-0.35
(0.13)**
-0.39
(0.15)**

0.18 (0.22)

-0.13
(0.22)
-0.16
(0.22)
0.01
(0.25)

-0.19
(0.19)
-0.18
(0.19)
-0.17
(0.21)

-0.05
(0.29)
-0.87
(0.61)
-0.93
(0.61)

-0.87
(0.61)
-0.93
(0.61)
-0.37
(0.69)

11.82
(7.39)
12.52
(7.42)
13.29
(8.35)

3.34
(4.82)
3.59
(4.84)
-1.18
(5.44)

-0.49
(0.21)*
-0.49
(0.09)*
-0.53
(0.24)*

0.02
(0.21)
-0.01
(0.21)
-0.12
(0.25)

-0.35
(0.18)*
-0.34
(0.18)*
-0.43
(0.20)*

2.56
(1.39)
2.72
(1.42)
2.50
(1.56)

5.91
(2.89)*
5.58
(2.90)
2.85
(3.48)

-0.03 (0.18)
-0.13 (0.21)

MED
180.01-387.30
Model 1
Model 2
Model 3

0.21 (0.27)
0.45 (0.31)

MED
387.31-2940.00
Model 1
Model 2
Model 3

MED
>2940.00
Model 1
Model 2
Model 3

0.08 (0.20)
0.06 (0.25)

0.16 (0.22)
0.28 (0.25)

Note: 1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B. Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use group. All other
measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
Model 1 = unadjusted model
Model 2 = adjusted for age, sex, and education
Model 3 = Model 2 + smoking, alcohol consumption, physical activity, stroke, diabetes, hypertension, BMI, depression & family history of dementia
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Table 22: Association between use of opioids (categorized according to quartiles of total morphine equivalent dose)and brain
volume in mm3 (mean and SD)

No use
Baseline
Follow-up
Change
MED
0.01-180.00
Baseline
Follow-up
Change
MED
180.01-387.30
Baseline
Follow-up
Change
MED
387.31-2940.00
Baseline
Follow-up
Change
MED
>2940.00
Baseline
Follow-up
Change

Total Brain

Left
Hippocampus

Right
Hippocampus

Left Entorhinal
Cortex

Right
Entorhinal
Cortex

Left
Amygdala

Right
Amygdala

White Matter
Hyperintensities

1570160.0 (169687.9)
1566683.3 (169687.4)
-3476.7 (6085.5)

4029.9 (442.6)
3969.9 (464.6)
-60.0 (16.3)***

4030.0 (427.1)
3939.0 (455.9)
-91.0 (15.8)***

2098.3 (315.2)
2043.9 (353.0)
-54.4 (12.0)***

1888.1 (342.4)
1818.2 (363.3)
-69.9 (12.7)***

1331.0 (217.0)
1295.0 (210.1)
-36.0 (7.7)***

1452.2 (249.5)
1434.3 (215.4)
-17.9 (8.6)*

3425.7 (3611.5)
4190.3 (4082.2)
764.6 (138.2)***

1585826.3 (161416.4)
1582349.5 (161416.4)
-3476.8 (21287.0)

3924.9 (335.0)
3833.8 (463.2)
-91.1 (53.3)

3905.5 (363.9)
3762.0 (420.2)
-143.5 (51.8)**

2011.5 (320.2)
2000.1 (374.6)
-11.4 (46.0)

1953.2 (314.2)
1848.6 (287.7)
-104.6 (39.7)**

1303.0 (180.5)
1298.2 (194.4)
-4.8 (24.7)

1458.4 (167.4)
1455.1 (207.8)
-3.3 (24.9)

3845.2 (3209.3)
4755.0 (3516.2)
909.8 (443.9)*

1541365.3 (191932.3)
1537888.5 (191932.3)
-3476.8 (40462.9)

3897.1 (494.8)
3794.6 (458.2)
-102.5 (100.5)

3824.9 (413.5)
3701.3 (516.6)
-123.6 (98.6)

2019.0 (179.3)
2013.8 (298.4)
-5.2 (51.9)

1877.1 (253.2)
1719.0 (209.9)
-158.1 (49.0)**

1284.0 (182.1)
1257.5 (145.4)
-26.5 (34.8)

1293.1 (212.0)
1338.7 (199.5)
45.6 (43.4)

2970.4 (1950.8)
3850.7 (2457.0)
880.3 (467.7)

1484896.9 (115863.3)
1481420.2 (115863.3)
-3476.7 (20323.8)

3842.7 (250.1)
3730.7 (311.6)
-112.0 (49.6)*

3708.9 (312.3)
3598.4 (317.7)
-110.5 (55.3)

1919.9 (127.8)
1786.7 (217.3)
-133.2 (31.3)***

1860.2 (277.4)
1753.2 (318.6)
-107 (52.4)*

1201.4 (140.5)
1201.6 (134.6)
0.2 (24.1)

1323.6 (222.9)
1305.9 (155.2)
-17.7 (33.7)

2459.2 (1421.0)
3185.1 (1723.6)
725.9 (277.1)*

1639535.3 (115813.4)
1636058.5 (115813.4)
-3476.8 (17264.4)

4038.3 (409.8)
3988.6 (473.3)
-49.7 (66.0)

4068.7 (480.8)
3967.8 (480.1)
-100.9 (71.6)

2298.9 (228.2)
2201.0 (318.1)
-97.9 (41.3)*

1994.0 (289.0)
1907.6 (337.3)
-86.4 (46.8)

1335.4 (199.0)
1299.7 (179.3)
-35.7 (28.2)

1431.5 (131.7)
1471.7 (174.5)
40.2 (23.0)

3679.7 (2691.4)
5218.2 (4474.7)
1538.5 (550.4)**

Note: measures represent brain volume in mm3. Negative values for change indicate decline in volume.
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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Table 23: Association between use of opioids (categorized according to quartiles of total morphine equivalent dose) and brain
volume in mm3 (β weights and SE)

MED
0.01-180.00
Model 1
Model 2
Model 3
MED
180.01-387.30
Model 1
Model 2
Model 3
MED
387.31-2940.00
Model 1
Model 2
Model 3
MED
>2940.00
Model 1
Model 2
Model 3

Total Brain

Left
Hippocampus

Right
Hippocampus

Left
Entorhinal
Cortex

Right
Entorhinal
Cortex

Left
Amygdala

Right
Amygdala

White Matter
Hyperintensities

-0.01 (0.02)
-0.01 (0.03)
-0.01 (0.03)

-31.16 (54.48)
-45.82 (53.89)
-55.02 (63.03)

-52.52 (51.29)
-72.94 (50.81)
-75.53 (57.25)

43.06 (49.78)
41.85 (49.35)
40.80 (54.05)

-34.74 (41.28)
-37.90 (41.27)
-42.80 (47.44)

31.11 (26.72)
34.71 (26.98)
17.46 (28.67)

14.63 (30.03)
16.02 (30.10)
19.49 (33.63)

145.23 (270.47)
115.77 (271.34)
-8.97 (293.74)

-0.0004 (0.04)
0.002 (0.04)
-0.02 (0.06)

-42.56 (79.35)
-52.06 (80.22)
-37.32 (104.22)

-32.54 (78.06)
-31.67 (78.15)
2.40 (99.12)

49.25 (76.51)
66.90 (75.86)
74.90 (99.98)

-88.18 (58.67)
-93.54 (59.19)
-153.76 (81.84)

9.54 (39.36)
12.61 (39.68)
4.77 (53.20)

63.54 (45.69)
67.58 (45.92)
87.55 (61.91)

115.69 (419.55)
16.10 (425.91)
181.29 (564.46)

0.05 (0.04)
0.05 (0.04)
0.04 (0.04)

-52.06 (85.39)
-81.67 (86.29)
-99.68 (90.31)

-19.53 (78.70)
-54.68 (79.01)
-44.90 (78.02)

-78.82 (70.59)
-48.63 (69.98)
-29.18 (82.51)

-37.18 (58.80)
-39.21 (60.11)
-47.49 (68.96)

36.15 (40.04)
34.85 (41.10)
-5.55 (43.45)

0.22 (39.92)
-5.11 (41.13)
-18.97 (49.49)

-38.64 (428.40)
-110.19 (428.69)
-128.82 (486.78)

-0.01 (0.03)
-0.01 (0.03)
-0.06 (0.04)

10.20 (60.33)
16.29 (61.20)
-15.13 (89.58)

-9.85 (64.79)
4.74 (64.25)
41.44 (91.34)

-43.45 (62.82)
-49.34 (62.55)
-56.76 (94.00)

-16.48 (46.92)
-19.97 (48.10)
-79.64 (63.96)

0.26 (32.63)
4.27 (34.38)
-21.81 (46.09)

58.16 (37.81)
64.46 (38.56)
69.63 (51.15)

773.92 (360.75)*
738.08 (359.33)*
366.59 (454.66)

Note: : Measures represent brain volume in mm3. Thus, negative β values indicate greater volume loss relative to no anticholinergic use group.
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
Model 1 = unadjusted model
Model 2 = adjusted for age, sex, and education
Model 3 = Model 2 + smoking, alcohol consumption, physical activity, stroke, diabetes, hypertension, BMI, depression & family history of dementia
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Table 24: Effect modification of the association between use of opioids (categorized according to quartiles of total morphine
equivalent dose) and cognitive function (β weights and SE) by apolipoprotein (APOE) ε4 allele
MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail A10

Trail B11

-0.12
(0.25)
0.55
(1.09)

0.37 (0.46)

0.16
(0.43)
1.05
(1.61)

-0.04
(0.38)
0.56
(1.78)

0.31
(0.53)
-1.16
(2.56)

-1.00
(1.13)
1.91
(5.04)

11.65
(13.99)
-19.59
(55.58)

-11.08
(9.03)
5.01
(36.04)

-0.11
(0.39)
1.38
(1.98)

0.26
(0.36)
0.71
(1.57)

0.27
(0.32)
-0.07
(1.43)

-0.84
(2.54)
-0.37
(11.29)

-8.72
(6.30)
-30.34
(22.74)

-0.33
(0.39)
0.49
(1.27)

-0.79 (0.60)

-0.68
(0.61)
-4.09
(2.13)

0.08
(0.55)
-1.22
(1.86)

-0.87
(0.82)
-0.42
(2.51)

-0.74
(2.02)
4.21
(6.09)

-19.57
(22.31)
-18.48
(72.85)

-18.19
(46.99)
-18.99
(46.99)

0.85
(0.58)
-0.59
(2.05)

0.47
(0.57)
-3.09
(1.93)

0.34
(0.52)
-2.40
(1.69)

-0.07
(3.80)
-30.47
(13.15)*

-3.08
(8.35)
-18.81
(29.03)

-0.004
(0.31)
0.06
(0.77)

0.02 (0.51)

-0.36
(0.48)
-1.29
(1.27)

-0.17
(0.46)
-0.56
(1.12)

-0.25
(0.59)
-0.19
(1.51)

0.23
(1.45)
0.37
(3.70)

16.32
(16.67)
3.10
(43.70)

10.46
(12.18)
10.85
(28.38)

-0.04
(0.53)
-1.27
(1.25)

0.47
(0.49)
-0.56
(1.19)

0.41
(0.40)
0.71
(1.02)

2.11
(3.05)
-7.23
(7.92)

0.61
(7.98)
-13.48
(17.43)

-0.07
(0.36)
1.73
(1.26)

-0.49 (0.53)

-0.55
(0.55)
-7.38
(2.12)***

0.05
(0.47)
-1.16
(1.84)

0.76
(0.62)
-0.75
(2.49)

-2.29
(1.45)
3.38
(6.02)

-8.15
(19.06)
39.91
(72.15)

9.21
(13.84)
59.84
(46.66)

0.29
(0.50)
0.99
(2.03)

0.21
(0.51)
-3.14
(1.92)

0.32
(0.46)
2.27
(1.68)

-1.23
(3.21)
18.61
(13.08)

7.12
(7.21)
62.83
(28.87)*

MED
0.01-180.00
+/+/+

-0.30 (1.87)

MED
180.01-387.30
+/+/+

-1.10 (2.13)

MED
387.31-2940.00
+/+/+

MED
>2940.00
+/+/+

-0.03 (1.27)

-5.71
(2.10)**

Note:1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B. Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use group. All other
measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
+/- = Presence of one APOE-ε4 allele
+/+ = Presence of two APOE-ε4 allele
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Table 25: Effect modification of the association between use of opioids (categorized according to quartiles of total morphine
equivalent dose) and brain volume in mm3 (β weights and SE) by apolipoprotein (APOE) ε4 allele
Total Brain

Left
Hippocampus

Right
Hippocampus

Left Entorhinal
Cortex

Right Entorhinal
Cortex

Left
Amygdala

Right
Amygdala

White Matter
Hyperintensities

MED
0.01-180.00
APOE-ε4

0.05 (0.07)

-30.23 (158.90)

73.66 (139.42)

22.49 (125.77)

31.85 (105.07)

57.31 (65.76)

-7.17 (79.97)

453.97 (701.52)

MED
180.01-387.30
APOE-ε4

-0.04 (0.09)

76.79 (162.50)

92.27 (158.70)

42.28 (156.19)

172.84 (139.15)

15.47 (90.20)

-32.28 (99.47)

-361.84 (891.27)

MED
387.31-2940.00
APOE-ε4

0.01 (0.09)

-57.05 (182.52)

-71.63 (163.59)

-28.76 (170.48)

129.40 (125.11)

70.34 (90.88)

8.21 (101.82)

-326.72 (1134.04)

MED
>2940.00
APOE-ε4

0.03 (0.06)

16.09 (143.53)

-121.68 (131.58)

63.25 (133.28)

169.48 (103.86)

30.14 (72.70)

-14.33 (79.46)

791.58 (635.38)

Note: : Measures represent brain volume in mm3. Thus, negative β values indicate greater volume loss relative to no anticholinergic use group.
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
APOE-ε4 = Presence of one or two APOE-ε4 allele
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CHAPTER 9
CONCLUSION AND RECOMMENDATIONS
SUMMARY OF FINDINGS
Trends in anticholinergic and opioid prescription in the elderly from 2004 to 2015
In this first study, we examined the temporal prescription trend of medications with
anticholinergic properties and opioids in the 60+ cohort of the PATH Through Life study.
Through this descriptive study, we aimed to highlight that these potentially inappropriate
medications are still commonly prescribed in a sample of community dwelling older adults. We
also aimed to further investigate if this trend decreases as the individuals age, indicating more
caution in prescribing habits of healthcare professionals. We found that the trend of prescribing
medications with anticholinergic properties continued to increase during the study period,
particularly for medications that showed moderate anticholinergic properties. While the
prescribing trend of opioids increased from the year 2004 to 2011, this trend changed and
declined from 2011 to 2015.
The effect of anticholinergic use on cognition and brain volume of older adults
In our second study, we examined if cumulative use of medications with anticholinergic
properties over a period of 4 years is associated with decline in cognitive function and brain
volume in the 60+ cohort of the PATH Through Life study. We found that cumulative use of
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anticholinergics over a period of 4 years, exceeding a total standardized daily dose of 1095 is
significantly associated with decline in Trail Making Test Part B scores. This indicates that
exposure to anticholinergics at this level impairs executive function in older adults. We also
found that among those with this highest level of exposure, individuals who had two
apolipoprotein E ε-4 alleles had significantly greater decline in their Trail Making Test Part B
scores compared to those without the alleles. Finally, we found that exposure to anticholinergics
did not affect brain volume during the study period.
The effect of opioids on cognition and brain volume of older adults
In our final study, we investigated the effect of cumulative opioid use in a period of 4
years on cognitive function and brain volume of older adults in the PATH Through Life Study.
We found that individuals who had a cumulative opioid exposure exceeding a total morphine
equivalent dose (MED) of 2940 had significantly lower Mini Mental State Examination (MMSE)
scores, indicating decline in global cognition. We also found that among those with this highest
level of cumulative opioid exposure, individuals with two apolipoprotein E ε-4 alleles had
significantly greater decline in their Immediate Recall and Delayed Recall assessment compared
to those without the alleles. In our study, we found that exposure to opioids during the study
period did not significantly affect brain volume of older adults.
CONTRIBUTION TO LITERATURE
Findings from this dissertation provide important information to address the gaps in
the literature on the inappropriate use of medications on cognitive function and brain volume of
older adults. In our first study, we provide important information to aid the understanding of
prescribing trends of these medications in a population of community dwelling older adults in
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Australia. In our second and third study, we address the gaps in the literature on the effect of
these medications on the different domains of cognition, allowing us to understand the effect of
these medications on a broad spectrum of cognitive function as opposed to the general global
cognition approach many studies have taken. By assessing if the association between
anticholinergics and opioids, and cognitive and brain volume outcomes are modified by the
APOE ε-4 allele, this dissertation provides important information on the potential acceleration of
cognitive impairment by these medications in individuals with a genetic risk factor for
Alzheimer’s disease.
STRENGTHS
The PATH Through Life study provided a large community dwelling older adult
population for us to study.(324) This allowed us to investigate the impact of these medications
on older adults without severe co-morbidities, which would have been strong confounders in the
analysis. It also increased the generalizability of our findings to other older adult populations. By
looking at cognitive function from a multi-domain perspective, we were able to study the impact
of anticholinergics and opioids on different cognitive domains. The MRI sub-study provided the
opportunity to study structural changes in the brain in terms of volumetric measures and white
matter lesions, to better understand the effects of these medications beyond symptomatic
outcomes.
We were also able to adjust for important covariates, as the PATH study collects data on
multiple variables. One such important variable was the apolipoprotein E (APOE) epsilon 4 (ε4)
genotype. We were able to assess if APOE ε-4 allele modified the association between the use of
anticholinergics and opioids, and cognitive function and brain volume. Further analysis on this is
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shown in Appendix B to Appendix E. By obtaining medication information from a database such
as the PBS, we were able to objectively quantify anticholinergic and opioid exposure according
to reliable standards of exposure measures for both, eliminating recall bias that may have
happened if we had to use self-reported medication use.(342)
LIMITATIONS
The PBS database is an administrative database that captures information on prescribed
and filled medications. As such, we were not able to obtain information on medications
adherence and use. Many anticholinergics are sold over the counter (2, 361) and this information
is not included in our analysis. We also took a conservative approach in classifying the exposure.
Individuals with no prescription information were classified as unexposed. These limitations may
have misclassified the exposure by under representing the exposed group and thus
underestimated the measure of association found in our studies. For our studies, we only looked
at Wave 2 and 3 of the PATH study, resulting in a 4-year follow-up. This is a relatively short
follow-up to observe change in cognitive function.
PUBLIC HEALTH IMPLICATIONS:
The findings from this dissertation have important public health implications.
Anticholinergics and opioids are commonly used in the older population. Although prescribing
guidelines caution against their use, many older adults are exposed to these medications.(4)
Given the increased utilization (10, 28, 29, 249) and the potential severity of side effects these
medications have on older adults,(16, 31, 32, 34) particularly on their cognitive function, relying
of guidelines alone is not sufficient to bring about change. As potential inappropriate use of
anticholinergics and opioids is a modifiable risk factor for cognitive impairment and other
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adverse effects in older adults, steps to prevent misuse can greatly reduce the related negative
outcomes.
Health promotion activities to support healthy aging must include steps to educate and
create awareness among older adults on the effects of their medications. Health education
improves health behavior and empowers older adults to practice good self-management of their
conditions.(362) Increasing awareness among older adults and their caregivers about the
potential adverse effects of their medications will empower them to advocate for their care and
potentially reduce the use of these medications in the elderly population.
Particularly with the gravity of the opioid public health crisis, findings from this
dissertation support the actions to allocate resources and to push for innovative ideas to address
pain management and reduce opioid use in older adults. Opioid use in the elderly population is
still a controversial topic, with some healthcare practitioners advocating for the cause and others
arguing for more caution and modulated used in geriatric populations.(363) An important step in
creating a consensus in this debate is the availability of studies, such as in this dissertation, to
support evidence based practices in opioid use among older adults.
FUTURE DIRECTIONS:
This dissertation lays the important first steps towards future studies that will provide
valuable insights on the effect of anticholinergics and opioids on cognitive function and brain
volume. The PATH Through Life study is an ongoing longitudinal cohort study. While analysis
in this dissertation utilized data from Wave 1 to Wave 3, future studies using data up to the
current Wave 5 will be able to assess the impact of longer exposure period to these medications.
This dissertation focused on the 60+ cohort. Given that conditions such as dementia, which result
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in cognitive impairment, can have a long prodromal period,(364) future studies looking at the
40+ cohort can provide insights on the impact of these medication in mid-life.
Studies investigating the effect of anticholinergics on cognition can take several other
approaches to address the gaps in the literature. Studies designed to investigate the effect of
anticholinergic burden on cognitive function and brain volume based on medication class can
provide valuable information. As the frontal cortex of the brain plays a critical role in the
cholinergic system in the central nervous system,(365, 366) assessing the impact of medications
with anticholinergic properties on frontal cortex volume will be very informative. Studies
investigating the effect of opioids can also take several other approaches. These include
quantifying opioid exposure as number of days exposed to opioids, which is an informative
measure of chronic exposure,(367) and understanding the association between opioid use and
cognitive function in those with and without cancer related pain.
CONCLUSION:
In summary, the findings of this dissertation provide important information on the effect
of anticholinergics and opioids on cognitive function and brain volume of older adults. The
results suggest that these medications affect overall cognition through impairment in different
cognitive domains. However, findings from this dissertation do not show any adverse effect on
brain volume and white matter lesions. This supports the need to approach the use of these
medications with caution in older adult populations.
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APPENDIX B: Effect modification of the association between use of anticholinergic medications (categorized according to
clinical significance) and cognitive function (β weights and SE) by apolipoprotein (APOE) ε4 allele (having at least one allele
compared to none)

TSDD
1-90
APOE-ε4
TSDD
91-365
APOE-ε4
TSDD
366-1095
APOE-ε4

MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail
A10

Trail B11

0.07
(0.30)

-0.28
(0.48)

-0.17
(0.49)

-0.14
(0.39)

-0.28
(0.54)

0.35
(1.30)

-23.18
(17.29)

-8.84
(12.38)

0.01
(0.51)

-0.05
(0.45)

-0.29
(0.40)

-2.43
(3.05)

-0.09
(6.14)

0.04
(0.53)

-0.14
(0.82)

-0.17
(0.81)

-0.73
(0.86)

1.02
(1.05)

-1.03
(2.61)

-33.98
(28.77)

-21.01
(20.73)

0.15
(0.78)

-0.40
(0.77)

-0.68
(0.69)

1.91
(5.13)

-0.14
(12.57)

0.98
(0.46)*

-0.54
(0.78)

-1.89
(0.78)*

-0.35
(0.76)

-0.12
(0.91)

1.59
(2.13)

-13.49
(26.53)

-9.92
(17.95)

-0.18
(0.80)

0.03
(0.69)

-0.06
(0.62)

0.39
(4.62)

23.51
(10.22)*

TSDD
>1095
APOE-ε4

0.27
0.32
-0.07
-0.22
0.83
1.64
6.42
3.94
-0.06
0.18
0.25
-3.97
-9.78
(0.25)
(0.36)
(0.35)
(0.35)
(0.48)
(1.06)
(12.17)
(8.52)
(0.35)
(0.32)
(0.30)
(2.23)
(4.96)*
Note: 1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B.

Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use
group. All other measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001

152

APPENDIX C: Effect modification of the association between use of anticholinergic medications (categorized according to
clinical significance) and cognitive function (β weights and SE) by apolipoprotein (APOE) ε4 allele (having two alleles
compared to one allele)

TSDD
1-90
+/+
TSDD
91-365
+/+
TSDD
366-1095
+/+

MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail
A10

Trail B11

-0.58
(0.79)

-1.62
(1.33)

-1.18
(1.34)

-0.87
(1.16)

0.83
(1.58)

0.69
(3.81)

-25.71
(45.48)

4.50
(29.91)

-1.75
(1.34)

-0.03
(1.24)

0.13
(1.06)

-6.00
(8.56)

-6.52
(18.65)

-0.56
(1.36)

-1.18
(2.24)

-2.67
(2.23)

-1.92
(1.95)

5.64
(2.64)*

5.50
(6.46)

-76.12
(76.54)

-17.03
(50.16)

0.64
(2.13)

-0.56
(2.04)

1.67
(1.79)

-8.30
(13.90)

38.44
(30.20)

0.77
(1.0)

-1.97
(1.67)

-2.27
(1.68)

-0.58
(1.46)

0.37
(1.94)

3.61
(4.72)

46.76
(56.58)

49.53
(37.63)

0.98
(1.61)

-0.70
(1.54)

0.10
(1.33)

11.13
(10.28)

66.69
(22.39)**

TSDD
>1095
+/+

0.70
0.17
0.39
0.52
0.16
-2.41
8.26
8.24
-1.71
-0.09
0.50
-8.65
-22.53
(0.69)
(1.15)
(1.17)
(1.02)
(1.39)
(3.26)
(38.92)
(25.35)
(1.12)
(1.07)
(0.91)
(7.17)
(16.24)
Note: 1Mini Mental State Examination, 2Digit Span Backwards Test, 3Spot-the-Word Test, 4Symbol Digit Modalities Test, 5Simple Reaction Time, 6Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B.

Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use
group. All other measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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APPENDIX D: Effect modification of the association between use of opioids (categorized according to quartiles of total
morphine equivalent dose) and cognitive function (β weights and SE) by apolipoprotein (APOE) ε4 allele (having at least one
allele compared to none)
MMSE1
MED
0.01-180.00
APOE-ε4
MED
180.01-387.30
APOE-ε4
MED
387.31-2940.00
APOE-ε4

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail
A10

Trail
B11

-0.08
(0.25)

0.34
(0.47)

0.20
(0.43)

-0.01
(0.35)

0.24
(0.53)

-0.83
(1.14)

10.24
(13.54)

-10.31
(9.02)

-0.03
(0.38)

0.27
(0.36)

0.24
(0.32)

-0.90
(2.46)

-9.82
(6.10)

-0.28
(0.38)

-0.81
(0.59)

-0.88
(0.60)

0.01
(0.54)

-0.84
(0.80)

-0.44
(1.95)

-19.48
(21.75)

-18.19
(14.44)

0.77
(0.57)

0.26
(0.56)

0.18
(0.51)

-1.83
(3.70)

-3.98
(8.19)

-0.002
(0.29)

0.01
(0.49)

-0.46
(0.46)

-0.22
(0.44)

-0.25
(0.56)

0.20
(1.40)

15.07
(16.10)

10.45
(11.73)

-0.17
(0.51)

0.39
(0.47)

0.45
(0.39)

1.34
(2.92)

-0.54
(7.52)

SDMT
4

MED
>2940.00
APOE-ε4

0.01
-0.71
-0.84
0.01
0.70
-2.02
-6.08
11.42
0.32
0.05
0.40
-0.45
9.39
(0.36)
(0.52)
(0.53)
(0.46)
(0.61)
(1.43)
(18.64)
(13.44)
(0.49)
(0.50)
(0.45)
(3.17)
(7.09)
1
2
3
4
5
6
Note: Mini Mental State Examination, Digit Span Backwards Test, Spot-the-Word Test, Symbol Digit Modalities Test, Simple Reaction Time, Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B.

Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use
group. All other measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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APPENDIX E: Effect modification of the association between use of opioids (categorized according to quartiles of total
morphine equivalent dose) and cognitive function (β weights and SE) by apolipoprotein (APOE) ε4 allele (having two alleles
compared to one allele)

MED
0.01-180.00
++
MED
180.01-387.30
++
MED
387.31-2940.00
++

MMSE1

Immediate
Recall

Delayed
Recall

Digit
Back2

Spot3

SDMT4

SRT5

CRT6

PPEG
(DH)7

PPEG
(NDH)8

PPEG
(BH)9

Trail
A10

Trail
B11

0.67
(1.11)

-0.67
(1.80)

0.89
(1.59)

0.61
(1.89)

-1.48
(2.54)

2.91
(5.00)

-31.24
(57.64)

16.09
(35.71)

1.49
(2.04)

0.46
(1.57)

-0.33
(1.43)

0.47
(11.69)

-21.62
(23.66)

0.82
(1.30)

-0.31
(2.18)

-3.41
(2.18)

-1.30
(1.89)

0.45
(2.59)

4.95
(6.28)

1.09
(74.57)

-0.79
(48.03)

-1.44
(2.08)

-3.56
(1.99)

-2.74
(1.73)

-30.39
(13.48)

-15.72
(29.54)

0.07
(0.79)

-0.04
(1.32)

-0.93
(1.31)

-0.40
(1.16)

0.07
(1.56)

0.14
(3.79)

-13.22
(45.03)

0.38
(29.28)

-1.23
(1.28)

-1.04
(1.19)

0.30
(1.04)

-9.34
(8.30)

-14.08
(18.90)

MED
>2940.00
++

1.80
-1.20
-1.51
5.67
48.06
50.63
0.70
-3.35
1.94
19.84
55.71
-5.22
-6.83
(1.29)
(1.87)
(2.56)
(6.11)
(73.69)
(48.12)
(2.07)
(1.97)
(1.72)
(13.27)
(29.51)
(2.14)**
(2.15)**
1
2
3
4
5
6
Note: Mini Mental State Examination, Digit Span Backwards Test, Spot-the-Word Test, Symbol Digit Modalities Test, Simple Reaction Time, Choice Reaction Time,
7Purdue Pegboard Test (Dominant Hand), 8Purdue Pegboard Test (Non-dominant hand), 9Purdue Pegboard Test (Both hands), 10Trail Making Test Part A, 11Trail Making Test Part
B.

Measures for Trail A, Trail B, SRT, and CRT represent response time. Thus, positive β values indicate poorer performance relative to no anticholinergic use
group. All other measures represent number of items completed correctly (negative β values indicate poorer performance).
*indicates significance at P<0.05 **Indicates significance at P<0.01 ***indicates significance at P<0.001
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